Advent Annuual Report-2018-19 PDF

TABLE OF CONTENTS
Letter of Transmittal 01
Notice of the 12th Annual General Meeting 02
Corporate Profile 03
Brief History of the Company 04
Vision, Mission and Values Statement 05
Board of Directors and Management of the Company 06
Brief Profile of the Board of Directors 07
Message From The Chairman 09
Message From The Managing Director 10
Directors’ Report to the Shareholders 11
Financial Highlights 22
Factory View 24
CEO & CFO’s Declaration to the Board of Directors 27
Certificate of Compliance of Corporate Governance 28
Report on Compliance of Corporate Governance Guidelines 29
Information Relating to Capital Structure 41
Audit Committee Report 42
Nomination and Remuneration Committee Report 44
Status of Credit Rating 46
Application of International Financial Reporting Standards (IFRSs) and
International Accounting Standards (IASs) 46
Auditors’ Report and Audited Financial Statements 47
Proxy Form & Attendance Slip 100
Letter of Transmittal
To
The Shareholders
Bangladesh Securities and Exchange Commission (BSEC)
Registrar of Joint Stock Companies & Firms (RJSC)
Dhaka Stock Exchange Limited
Chittagong Stock Exchange Limited
Subject: Annual Report for the year ended 30th June 2019.
Dear Sir(s),
We are pleased to enclose herewith a copy of the Annual Report together with the Audited Financial Statements including
Statement of Financial Position as at 30 June 2019, Statement of Profit or Loss and Other Comprehensive Income,
Statement of Cash Flows, Statement of Changes in Equity for the year ended on 30 June, 2019, along with notes
thereon of Advent Pharma Limited for your kind information and record.
Thanking you
Sincerely Yours,
Sd/-
Md. Ikramul Islam
CompanySecretary
Annual Report - 01
Advent Pharma Limited
Rupayan Karim Tower, Level # 10, 80, Kakrail
V.I.P. Road, Ramna, Dhaka-1000,
Factory: Plot # B 50-54, BSCIC Industrial Estate, Dhamrai, Dhaka.
Notice of the 12th Annual General Meeting (AGM)
Notice is hereby given to all the Shareholders of Advent Pharma Limited that the 12th Annual General Meeting (AGM)
of the Company will be held on Thursday, December 12,2019 at 11.00 a.m. at the company’s registered office: Plot # B
50-54, BSCIC Industrial Estate, Dhamrai, Dhaka to transact the following business.
AGENDA
01. To receive, consider and adopt the Audited Financial Statements of the Company for the year ended 30 June 2019,
together with the report of the Directors’ and Auditors’ thereon.
02. To declare dividend as recommended by the Board of Directors.
03. To elect/re-elect Directors as per Articles of Association of the Company.
04. To appoint/re-appoint Statutory Auditors of the Company and Professionals for compliance of corporate governance
code and fix their remuneration.
05. To transact any other business with the permission of the Chair.
By order of the Board
Sd/-
Dated: Dhaka Md. Ikramul Islam
November 27, 2019 Company Secretary
Note:
01. The Shareholders whose names will appear in the Share Register of the Company or Depository Register of CDBL
as on the Record Date i.e. November 21, 2019 will be eligible to attend the 12th Annual General Meeting (AGM) and
qualify for the dividend.
02. A member entitled to attend and vote at the Annual General Meeting may appoint a Proxy to attend and vote in his/her
behalf. Proxy form must be affixed with requisite revenue stamp and must be submitted at the Head office of the
Company, not more than 48 hours before the time fixed for the meeting.
03. Admission to the meeting will be strictly depending on production of the attendance slip sent with the notice as well
as verification of signature of Members/ (S) and/or Proxy holders/(s).
04. Shareholders are requested to update their BO account with ETIN in their respective Brokerage House to avoid
deduction of 15% tax instead of 10% for individuals as per Section 54 of the amended Income Tax Ordinance, 1984.
N.B:In compliance with Bangladesh Securities and Exchange Commission’s Circular No.SEC/CMRRCD/2009-
193/154 dated October 24, 2013, no gift/gift coupon/food box/benefit in cash or in kind shall bedistributed/paid to the
Shareholders for attending the 12th Annual General Meeting.
Annual Report - 02
CORPORATE PROFILE
Name of the Company : Advent Pharma Limited
Legal Status : A Public Company limited by shares registered under companies

Act, 1994 and listed with Dhaka Stock Exchange Limited and
Chittagong Stock Exchange Limited.
Date of Incorporation : C-65459(2951)/2007 dated: 25.01.2007
Converted into Public Limited Company : 07-May-2016
Commencement of Commercial Operation : 01-March -2013
Production Capacity : Bolus Products (in Pcs): 15.12 Million Pcs/Year

Powder Products (in Kg): 1.13 Million Kg/Year
Liquid Products (in Litre):1.32 Million Litre/Year
Registered Office & Factory : Plot # B 50-54 BSCIC Industrial Estate, Dhamrai, Dhaka
Corporate Office : Rupayan Karim Tower, Level # 10, 80, Kakrail, V.I.P. Road, Ramna,
Dhaka-1000,
Nature of Business :The Company is a Pharmaceutical company which is engaged in

manufacturing, importing and marketing of animal health care
drugs, nutritional supplements and feed additives for livestock like
powder, bolus and liquid dosage forms.
Authorized Capital : BDT 1,000 million
Paid Up Capital : BDT 754.60 million
Date of Approval for IPO : January 11, 2018
Date of Listing with DSE : April 01, 2018
Date of Listing with CSE : March 28, 2018
Principal Bankers : Islami Bank Bangladesh Ltd., New Market Br, Dhaka.
DBBL, Satmasjid Road Br, IFIC Bank Ltd, Dhanmondi Br,
Shahjalal Islami Bank Ltd, Satmasjid Road Br.
Midland Bank Ltd., Dilkusha Corporate Br.
External Auditors : Ahmed Zaker & Co., Chartered Accountants

Green City Edge (Level-10),89 Kakrail, Dhaka-1000.
Tax Consultants & Legal Advisor : Nasir Uddin Ahmed, M. Com (Mgt.), L.L.B
48 & 49 Kakrail, Sky View Mamta Center, A-2(2nd Floor), Dhaka-1000.
Credit Rating Agency : Alpha Credit Rating Ltd.

Sadharan Bima Bhaban-2 (8th floor), 139 Motijheel C/A,
Dhaka-1000.
Company’s Website : www.adventpharmabd.com
E-mail : adventpharmaltd.bd@gmail.com
Annual Report - 03
BRIEF HISTORY OF THE COMPANY
Advent Pharma Limited (APL) is a Pharmaceutical company which is engaged in manufacturing, importing and market-
ing of animal health care drugs, nutritional supplements and feed additives for livestock such as powder, bolus and
liquid dosage forms. APL has earned a reputation as a successful animal health medicine manufacturer over the last
few years.
Advent Pharma Limited was incorporated as a Private Limited Company on 25th January, 2007 and subsequently
converted into a Public Limited Company on 7th May 2016 under Companies Act 1994 with the Registrar of Joint Stock
Companies and Firms, Dhaka, Bangladesh under the Companies Act, 1994. The Certificate of Incorporation number is
C-65459(2951)/2007.
The Company started its commercial operation on March 01, 2013.The Company gets consent for IPO (Initial Public
Offering) as on January 11, 2018 from Bangladesh Securities and Exchange Commission. Accordingly the company
listed with CSE (Chittagong Stock Exchange Ltd) as on March 28, 2018 and listed with DSE (Dhaka Stock Exchange
Ltd) as on April 01, 2018. Advent Pharma Limited starts its trade from April 12, 2018 at DSE (Dhaka Stock Exchange
Ltd) and CSE (Chittagong Stock Exchange Ltd).
Annual Report - 04
Vision Statement
To become the market leader of the veterinary pharmaceutical industry through increased
productivity advanced technological application with quality on the strengths of our well experi-
enced professionals.
Mission Statement
To meet up the market needsthrougha closer working relationship andmaintaining quality
customer service. To provide maximum value to our customers, and communities.
OUR VALUES
• Quality
• Customer Focus
• Accountability
• Transparency
• Innovation
• Continuous Improvement
Brief description of business strategy;

APL’s key strategic objectives are to:
The Company is committed to manufacture products with strict adherence to the Drug Administration Guideline. The
aim of the promoters is to generate opportunity of employment, significant contribution to GDP and help to develop
Forward & Backward linkage in the country. The management of the company has the following objectives:
1. To be dedicated for the production of animal health care drugs;
2. To fulfill the increasing demand of animal health care drugs in the national market with high quality products;
3. To make the project a model plant of producing animal health care products of highest quality and excellence in
competitive price.
Annual Report - 05
BOARD OF DIRECTORS AND MANAGEMENT
OF THE COMPANY
Board of Directors
Mr. A.K.M Shafiqul Alam, LLB Chairman

(Nominee Director of Blue Agro Tech Ltd.)
Mr. Wajhi Ahmed Managing Director
Mrs. Kazi Rina Alam Director
Mrs. Faria Binta Alam Director
Mr. Md. Tazul Islam Director
Mr. Mohammad Towhidul Islam Director

(Nominee Director of Horipur Feed Ltd.)
Mr. Asif Iqbal Chowdhury Director

(Nominee Director of Farmers Hopes Ltd.)
Mr. Mohammed Salim, MBA, FCMA Independent Director
Mr. Sheikh Karimuzzaman Independent Director
Audit Committee
Mr. Mohammed Salim, MBA, FCMA Chairman
Independent Director
Mr. Sheikh Karimuzzaman Member

Mr. Asif Iqbal Chowdhury Member

Mr. Ikramul Islam Member Secretary

Company Secretary
Nomination and Remuneration Committee (NRC)

Mr. A.K.M Shafiqul Alam Member

Mr. Mohammad Towhidul Islam Member

Mr. Ikramul Islam Member Secretary

Company Secretary
Annual Report - 06
PROFILE OF THE BOARD OF DIRECTORS
Mr. A.K.M Shafiqul Alam, LLB

Chairman
Mr. Advocate A.K.M Shafiqul Alam, son of Mr. Abdus Salam was born in illustrious family on March 01, 1952 at Dhaka,
Bangladesh. He completed the degree of LLB and started advocacy in the supreme court of Bangladesh. He has over
43 years working experiences in the field law practicing. He is the Nominee Director of Blue Agro Tech Ltd.
Wajhi Ahmed,
Managing Director
Wajhi Ahmed was born in a very prominence Muslim family at Dhaka in Bangladesh in the year 1961. He has a long
track of 33 years’ successful experiences in handling and managing the commercial, financial and marketing segments
of Gaco Pharmaceutical, a renowned pharmaceutical manufacturing enterprise of the country. He was the Director of
the said organization that deals in manufacturing of pharmaceutical products for human consumptions.
Kazi Rina Alam,

Director
Kazi Rina Alam was born an eminence Muslim family in Bangladesh in the year 1959. She has successful long experi-
ence of running and managing SME level business enterprise dealing with handicrafts and promotional gift items.
Faria Binta Alam,

Director
Faria Binta Alam was born in famous Muslim family in Bangladesh in the year 1986. She has LLM degree and she is a
practicing lawyer in the Supreme Court of Bangladesh. Mrs. Faria is highly proficient and result-oriented professional
lawyer with around 6 years of experience in the practicing field.
Mrs. Faria is a member of Panel Lawyers in Standard Bank Ltd. as well as in NCC Bank and she has the privilege to be
a Legal Adviser of Hotel Royal Palace Pvt. Ltd.
Md. Tazul Islam,

Director
Md. Tazul Islam, son of Sundor Ali was born in illustrious family on May 08, 1956 at Comilla, Bangladesh. Basically, he
was a Diploma Engineer over 33 years’ business experiences..
Mohammad Towhidul Islam,

Director (Nominee Director of Horipur Feed Ltd.)
Mohammad Towhidul Islam was born in 1987 in illustrious family of Bangladesh. He obtained BBA from Presidency
University & MBA (major in Finance) from BRAC University. He is also partly qualified in Institute of Chartered Accounts
in Bangladesh (ICAB). He has 12 years working experiences in Philip Morris International (PMI) and Rahman Rahman-
Huq, a member firm of KPMG International.
Asif Iqbal Chowdhury,

Director (Nominee Director of Farmers Hopes Ltd.)
Asif Iqbal Chowdhury, son of late Mafizul Islam Chowdhury was born in illustrious family of Gaibandha, Bangladesh in
the year 1971. He obtained BSS under Dhaka University and has over 15 years’ business experiences.
Annual Report - 07
Mohammed Salim,
Mohammed Salim, FCMA, MBA (UK), MIPA (AUS), CMA(USA), the independent director of Advent Pharma Ltd. was
born in October 31, 1963 in Bhola, Bangladesh. With his vast educational qualifications, he has over 27 years’ profes-
sional experiences in the field of Financial Management, General Management, Financial Analysis, Project financing,
Company Law, Budgeting & forecasting, etc. Out of his 28 years working experiences, he served as a General Manager
(Finance) of about 10 years at Power Grid Company of Bangladesh Ltd.
Sheikh Karimuzzaman,
Sheikh Karimuzzaman was born in a respectable Muslim family at Dhaka in the year 1968. He completed his Master of
Laws (LLM) from Southeast University in the year 2007. He started practice in the Supreme Court of Bangladesh in the
year 2010. He also completed BA (Hon’s.) MA in English from Dhaka University in the year 1990. Out of this, He also
achieved the degree of Master of Human Rights from Dhaka International University in the year 2006. He is a social
worker as well.
Annual Report - 08
MESSAGE FROM
THE CHAIRMAN
Bismillahir Rahmanir Rahim
Respected Members, Shareholders and other Stakeholders,
Assalamualaikum
It is a great pleasure for me to be here with you at the 12th Annual General Meeting of Advent Pharma Limited. On
behalf of the Board of Directors and myself, I express my heartfelt thanks and profound gratitude to you for your support
and confidence. It is also my privilege to present you Company’s Annual Report for the Year ended June 30, 2019 along
with our business performance. We are always trying to create the value for investment of the shareholders who have
pledge their trust on us over the years.
Advent Pharma Ltd.performed very well during the year 2018-2019. We believe that our endeavors and team work
have enabled the Company to maintain its profitability under competitive industry scenario.
In 2018-2019, the Company has achieved huge Revenue and growth in Profit comparing to the previous year. It is
expected that positive momentum will continue in the coming year. Based on performance and business results the
Board has recommended 2% Cash dividend and 10% Stock dividend totaling 12% dividend for the year 2018-2019.
Advent Pharma Limited recognizes that its people are its most valuable asset. Accordingly, the Company continued its
programs for development of its human resources being the key contributor to Company’s success. We value the
contributions of our employees to the organization and adopted policy to reward them accordingly.
At Advent Pharma Ltd. we are working for a better future for our stakeholders, customers, employees and society at
large. At this occasion, I would like to thank the employees, without whose efforts and commitments we would not have
earned such a strong business position. I would also like to extend my gratitude to the Bangladesh Securities &
Exchange Commission, Dhaka Stock Exchange Limited, Chittagong Stock Exchange Limited, Registrar of Joint Stock
Companies and Firms, National Board of Revenue, Central Depository Bangladesh Limited and our numerous share-
holders for their valuable guidance, support and cooperation at the time of our needs. Our commitment is to attain our
cherished mission through execution of prudent business strategies while ensuring that we contribute positively
towards the furtherance of our national economy.
Yours sincerely
Sd/-
A.K.M Shafiqul Alam, LLB
Chairman
Annual Report - 09
MESSAGE FROM THE
MANAGING DIRECTOR
It is a great pleasure and privilege for me to attend this 12th Annual General Meeting of Advent Pharma Limited along
with our distinguished shareholders. I am delighted to announce that 2018-2019 has been a successful year for the
Company. During this year the Company has also maintained its volume of revenue and profitability under highly
competitive industry scenario by means of improvement in the quality of products and customer satisfaction.
As we have mentioned in the last few years, achieving double-digit growth year after year in the pharmaceutical
business is becoming quite a challenge due to the paucity of new pharmaceutical products in the world. We have also
stressed that in this environment of low R&D productivity, it has become increasingly important to efficiently utilize the
full potential of existing product portfolio. To this end, we have implemented and piloted a number of ideas over the last
four years. I shall elaborate on the progress of our strategic actions later in this statement. We have attempted to
analyze the underlying factors for growth in the Bangladesh pharmaceutical market. While economic development is
undoubtedly a key determinant of market growth, it is not straightforward to quantify the relationship of an exogenous
factor such as GDP growth rate, with market growth because of the preponderance of a variety of factors influencing
performance. However, endogenous growth, which is the growth that pharmaceutical companies foster through various
promotional campaigns are much easier to identify and analyze. Looking at the performance of each molecule, it is
clear that the prospects of endogenous growth remain good in Bangladesh.
I believe that the dedication and commitment of all our employees towards our customers have been the main driving
force in our successful performance. Accordingly, I would thank our devoted workforce and would expect their similar
dedication in future. At the same time, I would also like to thank the members of the Board of Directors for their contin-
ued support to the Management of the Company. I also acknowledge with gratitude the relentlessness backing and
cooperation of our numerous stakeholders and earnestly thank them for their continued trust and confidence on us.
Thanking You
Sd/-
Wajhi Ahmed
Managing Director
Annual Report - 10
DIRECTORS’ REPORT

Dear Shareholders
Assalamualaikum
On behalf of the Board of Directors of Advent Pharma Limited, I welcome you all to the12th Annual General Meeting. It
is pleasure to present you the Audited Financial Statements of the Company for the year ended June 30, 2019,
Auditors’ Report and the Directors’ Report thereon Corporate Governance along with Company’s performance and
other matters in terms of Companies Act 1994, listing regulations of DSE and CSE, the guidelines issued by Bangla-
desh Securities and Exchange Commission (BSEC) and International Accounting Standards and other applicable rules
& regulations.
Background
C-65459(2951)/ 2007. The Company started its commercial operation on March 01, 2013.
The Company gets consent for IPO (Initial Public Offering) as on January 11, 2018. Accordingly the company listed with
CSE (Chittagong Stock Exchange Ltd) as on March 28, 2018 and listed with DSE (Dhaka Stock Exchange Ltd) as on
April 01, 2018. Advent Pharma Limited starts its trade from April 12, 2018 at DSE (Dhaka Stock Exchange Ltd) and CSE
(Chittagong Stock Exchange Ltd).
Revenue
The Company attained a growth of 51.99% during the year 2018-2019 as against 38.94% during the previous year
2017-2018. The national pharma market growth and that of the company during the past few years are given below:
Year National Market Growth Rate Company’s Growth Rate
2014-15 11.36% 35.00%

2015-16 15.18% 30.40%
2016-17 35.29% 24.86%
2017-18 10.94% 38.94%
2018-19 13.60% 51.99%
Average 17.27% 36.24%
Source: IMS Report, 2018

The growth trend indicate positive outlook. The growth of the economy at 7.86% during FY 2017-18 offers scope for
further growth in investment for expansion in this sector.
Annual Report - 11
The operating financial results of the Company for the year 2018-2019 as compared to previous year are
summarized hereunder:
Particular 2018-19 2017-18

Turnover 601,966,497 396,048,274
Gross Profit 283,819,921 173,532,438
Financial Expenses 5,741,191 5,749,880
Other Income 6,935,771 3,034,356
Net Profit Before Tax (NPBT) 211,960,605 94,611,028
Provision for Taxation 53,556,967 7,733,996
Net Profit After Tax (NPAT) 158,403,638 86,877,032
Gross Margin (Turnover) 47.15% 43.82%
Net Margin Before Tax 35.21% 23.89%
Net Margin After Tax 26.31% 21.94%
Earnings Per Share (EPS) BDT. 2.10 1.59
Number of Shares used to compute EPS 75,460,000 54,627,397
Industry outlook and possible future developments in the industry

Pharmaceutical sector of Bangladesh has been among those few countable sectors for which Bangladesh is proud of
at the international level. This industry is the second largest contributor to the government exchequer. As per Director
General of Drug Administration, there are roughly 272 licensed Companies in this sector, mainly dealing with the
Production of human drugs. As per report published in the Financial Express on 09 Jan 2017, Local companies account
for 97% of the drug sales in the local market, catering to a population of 160 million, while the remaining 3% is imported.
There was lack of due attention for the livestock sector in Bangladesh by the public and Private investors until the early
1990s. However, during the last 20 years both the public and private investment in livestock sector is quite remarkable.
A considerable number of dairy farms, poultry farms have started growing up.
Bangladesh is an agricultural country and livestock is playing a key factor for developing agricultural sector. Animal
health care drug of high quality with affordable price is the prime need of the hour to develop livestock sector. Analyzing
the size and ever increasing demand of the market for all types of medicines, feed additives (Vitamins, Minerals, amino
acids, etc.), biological, implants and related Products for livestock and companion animals, it is clearly evident that
animal health Products has a bright marketing Prospect in Bangladesh.
The promoters of Advent Pharma Ltd. have visualized exploring the opportunities and invested in this sector in order to
fulfill the increasing demand of Veterinary drugs and nutritional supplements in the existing local Market. We will make
full use of the market scope, our business potentials and dynamics to benefit over-proportionally from the accelerating
economic growth, while always keeping in mind the interests of our shareholders.
The company has been operating in the market for a long time with reputation and commitment. With long experience
in pharmaceutical manufacturing, we are confident and believe that we can hold on to our reputation as a quality manu-
facturer.
The production process at the factory has three steps inputs to derive three types of dosage forms i.e. Bolus, Powder
and Liquid. The production process has many interdependencies from each part of the process. An overview of the
production process is provided below in Production Flow Chart:
Annual Report - 12
A. Process Flow Sheet for Manufacture of Liquid Preparation
DISPENSING
SEIVING & SIFTING
ADDITION & MIXING
INPROCESS CHECK BY QA
FILLING INTO BOTTLES/CONTAINERS
LABELLING & PACKING
FINAL APPROVAL BY QA
TRANSFER TO FG STORE FOR SALES AND DISTRIBUTION
DELIVERY TO CUSTOMER
B. Process Flow Sheet for Manufacture of Powder Preparation
DISPENSING
SEIVING & SIFTING
DRYING BY FLUID BED DRYING
BLENDING IN CONE SHAPE BLENDER
INPROCESS CHECK BY QA
FILLING INTO SACHETS/PACKETS
LABELLING & PACKING
TRANSFER TO FG STORE FOR SALES AN DISTRIBUTION
Annual Report - 13
C. Process Flow Sheet for Manufacture of Bolus (Tablet)
DISPENSING
SEIVING & SIFTING
GRANULATION
DRYING BY FLUID BED DRYING
BLENDING IN CONE SHAPE BLENDER
INPROCESS CHECK
COMPRESSION INTO BOLUS (TABLET)
SORTING OUT
BLISTERING
LABELLING & PACKING
Annual Report - 14
Segment Reporting
The company operates only in one segment that is the pharmaceuticals manufacturing through the process of Manu-
facture of Liquid Preparation, Powder Preparation and Bolus (Tablet).
Investment Planning
Company is pursuing with a prudent plan for investment in capital assets and working capital in line with the goal of the
company or a suitable place.
Risk and Concerns

Changes in the existing global or national policies can have either positive or negative impacts for the company. Any
scarcity or price hike of raw materials due to change in policy in the international market might hamper the production
and profitability. Changes in forex rates might also affect the pricing and thereby the profitability of the Company.
The performance of the company may also be affected negatively by the political and economic instability both in Bang-
ladesh and worldwide.
Similarly, risks and concern of the industry depends on the Government polices as well. However, pharmaceuticals
industry being the potential industry have always enjoyed special consideration from all the successive Governments
and expectation is that it will continue to enjoy similar care and consideration from policy makers in the future. Unless
any policy change that may negatively and materially affect the industry as a whole, the business of the company is
expected not to be affected in the short run.
Discussion on cost of goods sold, gross margin and net profit margin
30-June-19 30-June-18
Profit from Operation
Amount Percentage Amount Percentage
Turnover 601,966,497 100% 396,048,274 100%
Cost of Goods Sold 318,146,576 52.85% 222,515,836 56.18%
Gross Profit 283,819,921 47.15% 173,532,438 43.82%
Net Profit for the year 158,403,638 26.31% 86,877,032 21.94%
Discussion on continuity of extra-ordinary gain or loss

Extraordinary gains or losses refer to infrequent and unusual gain or loss and which is not part of the Company’s
ordinary/day to day operations. As to the Company, there was no such gain or loss during the year under reporting.
Related party transactions

Related party transactions are presented in note no.30.00 of the notes to the financial statements.
Significant variance of financial statements

No significant variation occurred between quarterly and final results of the Company during the year ended June 30, 2019.
Utilization of IPO fund

The company raised total Tk. 200,000,000 (Taka Twenty Crore Only)by issuing ordinary shares through IPO. Of the Tk.
20, 00, 00,000 (Taka Twenty Crore Only) the company utilized total Tk.141, 240, 537(Taka Fourteen Crore Twelve Lac
Forty Thousand Five Hundred Thirty Seven Only) by June 30, 2019. Utilization includes by Construction of Building and
Other Civil Works of Tk.93, 117,710 (Taka Nine CroreThirty One Lac Seventeen Thousand Seven Hundred Ten Only),
Acquisition of Machineries and Equipments of Tk. 29,924,522 (Two crore Ninety Nine Lac Twenty Four Thousand Five
Hundred Twenty Two Only) and IPO expenses of Tk.18, 198,305 (Taka One Crore Eighty One Lac Ninety Eight Thou-
sand Three Hundred Five Only).
Annual Report - 15
From July 01, 2019 to September 30, 2019 the Company has further utilized Tk. 51,506,278 (TakaFive Crore Fifteen
Lac Six Thousand Two Hundred Seventy Eight Only) for Acquisition of Machinery and Tk. 6,951,490 (Taka Sixty Nine
Lac Fifty One Thousand Four Hundred Ninety Only) for Construction of Building and Other Civil Works and Tk.
301,695(Taka Three Lac One Thousand Six Hundred Ninety Five Only) for IPO expenses. Total utilized Tk.
81,430,800(Eight Crore Fourteen Lac Thirty Thousand Eight Hundred Only) for Acquisition of Machinery and Tk.
100,069,200 (Taka Ten Crore Sixty Nine Thousand Two Hundred Only) for Construction of Building and Tk.
18,500,000(Taka One Crore Eighty Five lac only) for I.P.O Expenses. upto September 30, 2019. It means that the
Company has utilized full amount of money which was raised through Initial Public Offering (IPO).
Compliance of Notification No. BSEC/CMRRCD/2006-158/207/Admin/80 dated 3 June 2018.

Board Size:
The number of Directors in the board of Directors of the company is nine (09) including two (02) Independent Director
that is line with notification given by BSEC.
Independent Directors
In terms of the provision under Corporate Governance Code(CGC), the Boards of Directors has appointed Mr. Mohammed
Salim, MBA, FCMA as Independent Directors of the company as on dated 05 January 2017 for a period of three years
and Mr. Sheikh Karimuzzaman as Independent Directors of the company as on 25 November 2018 for a period of three
years. They are well versed and experienced person.
Qualification of Independent Director

Mohammed Salim, MBA, FCMA
Mohammed Salim, FCMA, MBA (UK), MIPA (AUS), CMA (USA), the independent director of Advent Pharma Ltd. was
born in October 31, 1963 in Bhola, Bangladesh. With his vast educational qualifications, he has over 28 years’ profes-
sional experiences in the field of Financial Management, General Management, Financial Analysis, Project financing,
Company Law, Budgeting & forecasting, etc. Out of his 28 years working experiences, he served as a General Manager
(Finance) of about 10 years at Power Grid Company of Bangladesh Ltd. He is the successful president of The Institution
of Cost and Management Accountants of Bangladesh (ICMAB).
Sheikh Karimuzzaman,
Sheikh Karimuzzaman was born in a respectable Muslim family at Dhaka in the year 1968. He completed his Master of
Laws (LLM) from Southeast University in the year 2007. He started practice in the Supreme Court of Bangladesh in the
year 2010. He also completed BA (Hon’s.) MA in English from Dhaka University in the year 1990. Out of this, He also
achieved the degree of Master of Human Rights from Dhaka International University in the year 2006. He is a social
worker as well.
Chief Financial Officer, Company Secretary, Head of Internal Audit

As per corporate governance code of BSEC, the company has allocated the responsibilities of the officials as follows:
Chief Financial Officer : Mr. Md. Mohsin Mia
Company Secretary : Mr. Md. Ikramul Islam
Head of Internal Audit : Mr. Md. Ali Reza Zahurul Islam
Audit Committee
The Audit Committee, as a sub-committee of the Board has been constituted with the Independent Director Mr. Moham-
med Salim, MBA, FCMA as Chairman and two other Directors as members. The company Secretary acts as Member
Secretary to the Audit Committee. This committee assists the Board of the company in ensuring that the financial state-
ments reflect true and fair view of the state of affairs of the Company. Audit Committee is responsible to the Board of
Directors and its roles and responsibilities are clearly set forth. The roles and functions of the Audit Committee have
been stated in the annual audit committee report and it is annexed herewith.
Annual Report - 16
Nomination and Remuneration Committee (NRC)
The Nomination and Remuneration Committee (NRC), as a sub-committee of the Board of Director has been consti-
tuted with three board of directors with one Independent Director Mr. Mohammed Salim, MBA, FCMA as Chairman and
two other Directors as members. The company Secretary acts as Member Secretary to the Committee. The Nomination
and Remuneration Committee assists the Board in formulation of the nomination policy and criteria for determining
qualifications, experiences and independence of the directors. The committee also assists the board in setting policy
for attractive remuneration package for the directors in line with their appropriate performance and industry benchmark.
The roles and functions of the Nomination and Remuneration Committee have been stated in the annual Nomination
and Remuneration Committee report and it is annexed herewith.
External Statutory Auditors

The BSEC guidelines are being strictly followed in engaging statutory Audit for the Company.
Maintaining a website
The company has been maintaining an official website www.adventpharmabd.com which is linked with the website of
the stock exchange.
Subsidiary Company
The company has no subsidiary company whatsoever.
Duties of CEO and CFO

The provision of BSEC regulations have been compiled in the Annual Report.
Reporting and Compliance of Corporate Governance Code

Status of compliance with the conditions imposed by the Commission’s Notification No BSEC/CMRRCD /2006-
158/207/Admin/80 dated 03June 2018 issued under section 2CC of the Securities and Exchange Ordinance, 1969.
Directors’ Appointment and Re-Appointment

With regard to the appointment, retirement and re-appointment of directors, the company is governed by its Articles of
Association, the Companies Act. 1994 and other related legislations. Accordingly, the following Directors of the Board
will retire at the annual general meeting and be eligible to offer themselves for re-election:
1. Md. Tazul Islam
2. Faria Binta Alam
Shareholding pattern
The shareholding of directors at the end of 30 June, 2019 is shown as bellow:
Name of the shareholders Position Shares held %
i. Parent/subsidiary/associated Companies And Other Related Parties - -- -
ii. Directors:
Wajhi Ahmed Managing Director 1,672,000 2.22 %
Kazi Rina Alam Director 1,540,000 2.04 %
Faria Binta Alam Director 1,518,000 2.01 %
Md. Tazul Islam Director 1,540,000 2.04 %
Blue Agro Tech Ltd. Director 5,313,000 7.04 %
Horipur Feed Ltd. Director 5,310,250 7.04 %
Farmers Hopes Limited Director 5,313,000 7.04 %
Mohammad Jawaid Yahya Sponsor Director 1,518,000 2.01 %
Mohammed Salim Independent Director - -
Shekh Karimuzzaman Independent Director - -
iii. Managing Director, Chief Financial Officer, Company Secretary, Head Of Internal Audit And Their Spouse And Minor Children:
Wajhi Ahmed Managing Director 1,672,000 2.22 %
Md. Mohsin Mia Chief Financial Officer -
Md. Ikramul Islam Company Secretary - -
Md. Ali Reza Zahurul Islam Head Of Internal Audit - -
iv. Executives: - -
v. Shareholders Holding 10% Or More Voting Interest In The Company: - -
Annual Report - 17
Directors involved in other Companies:
Involvement with Other

Sl. Name Position in APL Companies
Companies Position
1 Wajhi Ahmed Managing Director -
2 Mohammad Jawaid Yahya Sponsor Director Not involved in other
3 Kazi Rina Alam Director organization -
4 Faria Binta Alam Director -
5 A.K.M Shafiqul Alam
Chairman Blue Agro Tech Ltd. Director
Managing
6 Md. Tazul Islam Director Horipur Feed Limited
Director
7 Mohammad Towhidul Islam
Director Horipur Feed Limited Director
8 Asif Iqbal Chowdhury
Director Farmers Hopes Ltd. Chairman
(Nominee Director of Farmers Hope Ltd.)
Asian Centre for
9 Mohammed Salim Independent Director Management and Director
Information Technology
Limited.
10 Sheikh Karimuzzaman Independent Director
Board Meeting and Attendance

During the year, 7 (Seven) nos. of Board Meetings were held. The attendance record of the directors is as given
below:
Name of Directors Attendance
A.K.M. Shafiqul Alam 5
Wajhi Ahmed 7
Mohammad Jawaid Yahya 2
Mahmood Ali 3
Kazi Rina Alam 7
Faria Binta Alam 7
Md. Tazul Islam 6
Mohammad Towhidul Islam 7
Asif Iqbal Chowdhury 7
Mohammed Salim 6
Sheikh Karimuzzaman 2
Shanzida Akhter Khanam 4
Director’s remuneration
Director’s remuneration is shown in the note no. 30.01 of the notes to the Financial Statements.
Directors’ Statement on Financial Reports

In accordance with the Bangladesh Securities and Exchange Commission Notification No. BSEC/CMRRCD/2006-
158/207/Admin/80 dated 03 June, 2018 the Directors are pleased to confirm the following:
a) The financial statements together with the notes thereon have been drawn up in conformity with the Companies
Act, 1994 and the Securities and Exchange Rules, 1987. These statements present fairly the company’s state of
affairs, the result of its operations, cash flows and changes in equity.
Annual Report - 18
b) Proper books of accounts of the company have been maintained.
c) Appropriate accounting policies have been applied consistently in preparation of the financial statements and the
accounting estimates are based on reasonable and prudent judgment.
d) International Accounting Standards (IASs)and International Financial Reporting Standards (IFRSs) as applicable in
Bangladesh have been followed in the preparation of the financial statements.
e) The system of internal control is sound and

- has been implemented and monitored effectively.
f) Minority shareholders have been protected from abusive actions by, or in the interest of, controlling shareholders
acting either directly or indirectly and have effective means of redress.
g) The key operating and financial data for the last five years have been presented in page no. 22.
h) No Bonus or stock dividend has been or shall be declared as interim dividend.
Going Concern
While approving the financial statements, the directors have made appropriate enquiries and analysed the significant
financial, operating as well as other indicators for enabling them to understand the ability of the company to continue
its operation for a foreseeable period. Directors are convinced and have a reasonable expectation that the company
has adequate resources to continue its operation consistently for the foreseeable future. Therefore the company
adopted the going concern basis in preparing the financial statements.
Significant deviation of Operating Result

There is no significant deviation from the last year’s operating result of the Company.
Dividend
The Board of Directors has recommended 2% Cash dividend and 10% Stock dividend.
Particulars 2019 2018

Profit available for appropriation
Profit/loss after Tax 158,403,638 86,877,032
Un-appropriated profit brought forward from previous year 187,950,804 119,272,077
Adjustment for IPO Expenses - (18,198,305)
Total Amount available for appropriation 346,354,442 187,950,804
Appropriation
Closing Retained Earning at year end (Before proposed final dividend) 346,354,442 187,950,804
Proposed Dividend for the year 2019 (2% cash and 10%stock) 90,552,000 82,320,000
Retained Earnings after proposed dividend 255,802,442 105,630,804
Statutory Auditors
The Auditors of the Company, M/S Ahmed Zaker & Co., Chartered Accountants,Green City Edge(Level-10), 89 Kakrail,
Dhaka-1000, Bangladeshhas carried out the audit of the company for the year ended 30 June, 2019. Due to unavoid-
able circumstances, company’s auditor K.M Hasan & Co., Chartered Accountants, approved by the shareholders on
11th Annual General Meeting held on 06.12.2018; resign from the post of auditor as on 17 March, 2019. The board
accepted the resignation of the existing auditor K.M Hassan & Co., Chartered Accounts and recommended appointing
Ahmed Zaker& Co., Chartered Accountants as an auditor at the Board of Directors Meeting held on 24.03.2019, after
getting expression their interest to work as auditor for the year ended June 30, 2019 with the remuneration of Tk.
2,30,000/= (Taka Two Lac Thirty Thousand only) including VAT. As per regulation 15 (2) & (3) of DSE and CSE (listing)
regulations, 2015 existing auditor is eligible for re-appointment. Accordingly the Board of Directors has recommended
for re-appointment of Ahmed Zaker& Co., Chartered Accountants, Green City Edge(Level-10), 89 Kakrail, Dhaka-1000,
Bangladeshat an annual fee of Tk.2,30,000/=(Taka Two Lac Thirty Thousand Only) including VAT . A proposal for
re-appointment of M/S Ahmed Zaker& Co., Chartered Accountants as auditor for the year 2019-20 of the Company will
be placed in the forthcoming 12th AGM for shareholder’s approval and fixation of their fees.
Annual Report - 19
Professionals for Compliance of Corporate Governance Code
Due to unavoidable circumstances, M/S Mazumdar Sikdar and Associates, Cost & Management Accountants has been
resigned from the post of professionals for Corporate Governance Code for the year 2018-2019. Board of Directors has
appointed M/S Podder & Associates, Cost and Management Accountants, 6/A/1 Segunbagicha (Ground Floor),
Dhaka-1000, Bangladesh, for the year 2018-19 and 2019-20 as professional for Corporate Governance Code, and be
placed before the shareholders for their approval and fixation of fees.
Acknowledgment
The Company expresses its sincere thanks and gratitude to the respected shareholders, valued clients, suppliers,
banks and well-wishers home and aboard for their wholehearted co-operation and active support.
We are thankful to the Bangladesh Securities and Exchange Commission (BSEC), Dhaka Stock Exchange Limited
(DSE), Chittagong Stock Exchange Limited (CSE), Registrar of Joint Stock Companies & Firms (RJSCF), Central
Depository Bangladesh Limited (CDBL), Government and private sector Organizations and other stakeholders for
extending co-operation and support to our company.
Thanks are also due to all directors, all executives, officers, staff and workers of the company for their excellent,
sincere, dedicated efforts in achieving company’s target during the year.
I, on behalf of the board of directors, take the opportunity to inform you that we welcome any suggestions and opinion
to improve our company performance and financial stability.
Thanking you.
On behalf of the Board of Directors
Sd/-
Mr. A.K.M Shafiqul Alam, LLB
Chairman
Annual Report - 20
Management Discussion and Analysis on Financial Position and Performance
Bangladesh has been enjoying a strong macroeconomic stability for a decade. Constant 6% plus economic growth has
been witnessed in this decade. As per provisional estimate of BBS, the GDP growth stood at 8.13% in FY 2018-19,
which was 7.86% in previous fiscal year. It is forecasted 8% plus in this FY 2019-2020. Per capita income has been
increasing constantly and it is predicted that it would be USD 1909 in the fiscal year 2018-2019. Earlier it was USD
1,751 in 2017-18, which was USD 1,610 in FY 2016-17. All are eyeing to be middle income country by 2027. In the fiscal
year 2019-2020, in the first quarter, our export growth has been slumped due to low demand from our exporting coun-
tries and we hope in the coming months it will be recovered with the concerted effort by the government and business
communities. Forex Reserve is around USD 32 billion and it is facing huge pressure because of high import as huge
development works are underway in the country. However, government has taken new initiatives by providing 2% cash
incentives for foreign remittance. We hope that it will boost up foreign reserve or at least manage the downward
pressure on forex reserve because of high import.
For last five financial years the company generated moderate growth in sales. In 2014, sales stood Tk. 165,737,267
and now in 2019 sales stand Tk. 601,966,497. In line with sales, net profit after tax had been increased from around Tk.
17,362,563 in 2014 to Tk.158,403,638 in 2019. In the last five financial years, net operating cash flow per share was
positive. In the backdrop of above scenario, it indicates the company is moving forward and it has good promise in the
long run.
Accounting policy and estimation for preparing financial statements have been remained same as it was before.
Hence, there is no effect in this regard.
As per report published in the Financial Express on 09 Jan 2017, Local companies account for 97% of the drug sales
in the local market, catering to a population of 160 million, while the remaining 3% is imported.
There was lack of due attention for the livestock sector in Bangladesh by the public and Private investors until the early
1990s. However, during the last 20 years both the public and private investment in livestock sector is quite remarkable.
A considerable number of dairy farms, poultry farms have started growing up.
Advent Pharma Ltd. have visualized exploring the opportunities and invested in this sector in order to fulfill the increas-
ing demand of Veterinary drugs and nutritional supplements in the existing local Market.
Sd/-
Wajhi Ahmed
Managing Director
Annual Report - 21
FINANCIAL HIGHLIGHTS
Amount in Taka
Operational Result 30 June 2019 30 June 2018 30 June 2017 30 June 2016 31 Dece 2014
(18 Months)
Turnover 601,966,497 396,048,274 285,059,543 330,967,356 165,737,267
Gross Profit 283,819,921 173,532,438 128,368,344 137,554,821 66,537,498
Profit from Operation 223,026,912 102,057,103 81,759,008 72,515,373 32,052,211
Net Profit before tax 211,960,605 94,611,028 74,906,779 63,581,549 26,711,635
Net Profit after Tax 158,403,638 86,877,032 48,689,408 41,328,007 17,362,563
Financial Position 30 June 2019 30 June 2018 30 June 2017 30 June 2016 31 Dece 2014
(18 Months)
Non-Current Assets 931,180,917 685,286,322 562,066,136 247,264,764 98,289,075
Current Assets 276,465,072 327,475,163 165,204,383 79,791,496 43,003,514
Shareholder's Equity 1,018,634,442 873,950,804 605,272,077 170,482,669 59,754,662
Current Liability 102,897,663 72,096,752 55,664,895 44,678,229 44,481,225
Long Term Liability 86,113,884 66,713,929 66,333,547 111,895,362 37,056,702
30 June 2019 30 June 2018 30 June 2017 30 June 2016 31 Dece 2014
Key Financial Ratio
(18 Months)
Current Ratio 2.69 4.54 2.97 1.79 0.97
Quick Ratio 1.63 3.31 1.55 1.03 0.54
Debt to Equity Ratio 0.03 0.06 0.07 0.26 0.91
Net Income Ratio (%) 26.31% 21.94% 17.08% 12.49% 10.48%
Return on Equity (%) 15.55% 11.75% 12.55% 35.90% 34.06%
Earnings Per Share 2.10 1.41 1.49 3.75 1.89
Annual Report - 22
FINANCIAL HIGHLIGHTS IN THE FORM OF GRAPHICAL
REPRESENTATION
Amount in Taka (Million)
1200
1018.63 SHAREHOLDER’S EQUITY
1000
873.95
800
605.27
600
400
170.48
200
59.75
0
30-Jun-19 30-Jun-18 30-Jun-17 30-Jun-16 31-Dec-14
Turnover
700 601.96
396.05
600
500 285.06 330.97
400
300 165.74
200
100
0
OPERATIONAL RESULT
300.00
250.00
200.00
150.00
100.00
50.00
-
Gross Profit Profit from Operation

Net Profit before tax Net Profit after Tax
Annual Report - 23
Factory View
Pictures of Factory, machineries, manufacturing process and products:
Annual Report - 24
Annual Report - 25
Our Newly Introduced & Upcoming Products:
Following Product has included in our portfolio after March 2018 (After Starting IPO)
Sl NO Name of Product Presentation

1 Adprozin Bolus 10x4 Blister Pack
2 Power Fat 1 kg Sachet
3 Oramin Solution 100 ml & 500 ml Bottle
4 Egg Boost 100 gm Powder
5 Germ Kill 100 ml & 500 ml Bottle
6 Adcipcin Bolus 10x2 Blister Pack
7 TCL Vet Bolus 5x4 Blister Pac
8 Keto Pain Bolus 10x4 & 5x4 Blister Pack
We have planned to launch the following products in the next Two months’ time:
1. Levamisole HCL BP 300 mg Powder
2. Sodium Carbonate BP 40 mg Solution
3. Antimony Potassium Tartrate USP 2 mg Ferrous Sulphate USP 2 mg bolus
4. Tolfenamic Acid BP 200 mg bolus
5. Norfloxacin BP 100 mg solution
6. Toltrazuril INN 25 mg Solution
7. Tilmicosin(As Phosphate) USP 250 mg solution
8. Levofloxacin USP 100 mg Solution
9. Colistin Sulphate BP 2400000 IU Solution
10. Toldimphos Sodium BP 2 gm bolus
11. Simethicone USP 10 mg Suspension
12. Ciprofloxacin inj. 100 mg/ml
13. Sodium Bicarbonate Inj 75 mg/ml
14. PheneramineInj 227.5 mg/ml
15. KetoprofenInj 100 mg/ml
16. Ivermectin Inj. 10 mg/ml
Annual Report - 26
Annexure-A
[As per condition No. 1(5)(xxvi)]
ADVENT PHARMA LIMITED

Declaration by CEO and CFO
Date: October 27, 2019
The Board of Directors

Rupayan Karim Tower, Level-10,
80 Kakrail, V.I.P Road, Ramna, Dhaka.
Factory: Plot # B 50-54, BSCIC Industrial Estate,
Dhamrai, Dhaka.
Subject: Declaration on Financial Statements for the year ended on June 30, 2019.
Dear Sirs,
Pursuant to the condition No. 1(5) (xxvi) imposed vide the Commission’s Notification No. BSEC/CMRRCD/2006-
158/207/Admin/80 dated 3 June 2018 under section 2CC of the Securities and Exchange Ordinance, 1969, we do
hereby declare that:
(1) The financial Statements of Advent Pharma Limited for the year ended on June 30, 2019 have been prepared in
compliance with International Accounting Standards (IASs) and International Financial Reporting Standards
(IFRSs),as applicable in the Bangladesh and any departure there from has been adequately disclosed;
(2) The estimates and judgments related to the financial statements were made on a prudent and reasonable basis,
in order for the financial statements to reveal a true and fair view;
(3) The form and substance of transactions and the Company’s state of affairs have been reasonably and fairly
presented in its financial statements;
(4) To ensure above, the Company has taken proper and adequate care in installing a system of internal control and
maintenance of accounting records;
(5) Our internal auditors have conducted periodic audits to provide reasonable assurance that the established policies
and procedures of the Company were consistently followed; and
(6) The management’s use of the going concern basis of accounting in preparing the financial statements is appropri
ate and there exists no material uncertainty related to events or conditions that may cast significant doubt on the
Company’s ability to continue as a going concern.
In this regard, we also certify that:-

(i) We have reviewed the financial statements for the year ended on 30 June 2019 and state that to the best of
our knowledge and belief:
(a) these statements do not contain any materially untrue statement or omit any material fact or contain statements
that might be misleading;
(b) these statements collectively present true and fair view of the Company’s affairs and are in compliance with
existing accounting standards and applicable laws.
(ii) There are, to the best of our knowledge and belief, no transactions entered into by the company during the year
which are fraudulent, illegal or in violation of the code of conduct for the company’s Board of Directors or its
members.
Sincerely yours,
Sd /- Sd /-
Mr.Wajhi Ahmed Md. Mohsin Mia
Managing Director & CEO Chief Financial Officer (CFO)
Annual Report - 27
Annexure-B
[Certificate as per condition No. 1(5)(xxvii)]
CERTIFICATE ON CORPORATE GOVERNANCE COMPLIANCE
Report to the Shareholders of Advent Pharma Limited on compliance on the Corporate Governance Code
We have examined the compliance status to the Corporate Governance Code by Advent Pharma Limited for the year
ended on June 30, 2019. This Code relates to the Notification No. BSEC/CMRRCD/2006-158/207/Admin/80, Dated: 3
June 2018 of the Bangladesh Securities and Exchange Commission.
Such compliance with the Corporate Governance Code is the responsibility of the Company. Our examination was
limited to the procedures and implementation thereof as adopted by the Management in ensuring compliance to the
conditions of the Corporate Governance Code.
This is scrutiny and verification and an independent audit on compliance of the conditions of the Corporate Governance
Code as well as the provisions of relevant Bangladesh Secretarial Standards (BSS) as adopted by Institute of Char-
tered Secretaries of Bangladesh (ICSB) in so far as those standards are not inconsistent with any condition of this
Corporate Governance Code.
We state that we have obtained all the information and explanations, which we have required, and after due scrutiny
and verification thereof, we report that, in our opinion:
(a) The Company has complied with the conditions of the Corporate Governance Code as stipulated in the above
mentioned Corporate Governance Code issued by the Commission except under conditions number 9(2);
(b) The Company has complied with the provisions of the relevant Bangladesh Secretarial Standards (BSS) as
adopted by the Institute of Chartered Secretaries of Bangladesh (ICSB) as required by this Code;
(c) Proper books and records have been kept by the company as required under the Companies Act, 1994, the securities
laws and other relevant laws ; and
(d) The governance of the company is satisfactory.
For Podder & Associates
Place: Dhaka. Sd/-

Date: 24th November 2019 Jayanta Kumer Podder
Cost & Management Accountants
Annual Report - 28
The APL’s Board is comprised of 9
Directors including the Managing
Director
02 out of 9 Directors are appointed

as independent Director
The independent Directors have

declare their compliances
Annual Report - 29
No vacancy occourd during the
reporting period
Annual Report - 30
No such incident arose
yet
The Director’s report complies with the guideline
N/A
Annual Report - 31
No such matter to explain
No such event arose
The Company has declared

10% stock & 2% cash dividend
N/A
Annual Report - 32
No shareholder holding 10%
or more share of the Company
N/A
Annual Report - 33
APL does not have any subsidiary Company
Annual Report - 34
In Practice
In Practice
In Practice
Disclosed in the Annual

Report
Audit Committee (AC) is comprised

of Three members including an
independent Director
All the AC members are non-

executive Directors inculuding
an Independent Director
Annual Report - 35
Annual Report - 36
N/A
The TOR is duly approved by

the Board
NRC is comprised of Three members

including an independent Director
All the NRC members are non-executive

Directors inculuding an Independent
Director
Annual Report - 37
The NRC members are duly appointed
by the Board
No such case in arose
No such occurence during the year
In Practice
Annual Report - 38
The policy criteria and activites of
NRC are disclosed in the Annual
Report
Annual Report - 39
Required certification has been
obtained from “PODDER &
ASSOCIATES” Cost &
Management Accountants for
the year ended 30th June 2019
Board recommended the

Professional for due appointment
by the Shareholders in
Upcoming AGM
Annual Report - 40
Information Relating to Company Capital
C-65459(2951)/2007. The company has been operating in the market for a long time with reputation and commitment.
The company has long experience in pharmaceutical manufacturing in Bangladesh. The Company started its business
with paid up Capital TK. 2.50 million and now its existing paid up capital stands at 754.60 million. Authorized Capital of
the Company is TK. 1000 million in 2017 the Company raised its paid up capital by TK. 200 million through IPO. The
Company is listed with DSE and CSE. The Capital Structure of the Company is the nominated as under:
Particulars Amount in Taka Percentage

Sponsor & Director : 237,242,500/- 31.44 %
Institution : 149,202,380/- 19.77 %
Public : 368,155,120/- 48.79 %
75,460,000/- 100.00 %
The Range of Shareholding as on 30 June, 2019

Percentage of
Particulars of Investors Number of Share
Shareholding (%)
1 to 500 Shares 234,679 0.311

501 to 5,000 shares 3,253,860 4.312
5,001 to 10,000 shares 2,591,077 3.434
10,001 to 20,000 shares 2,893,152 3.834
20,001 to 30,000 shares 1,933,284 2.562
30,001 to 40,000 shares 911,949 1.209
40,001 to 50,000 shares 1,329749 1.762
50,001 to 100,000 shares 4,011,085 5.316
100,001 to 1,000,000 shares 23,201,147 30.746
Over 1,000,000 35,100,018 46.515
Total 75,460,000 100.000
Annual Report - 41
Audit Committee Report (for the year ended 30 June 2019)
Dear Shareholders,
Advent Pharma Limited established an audit committee as a sub-committee of the Board of Directors and they assist
the Board of Directors in fulfilling its oversight responsibilities and ensuring that the financial statement reflects true and
fair view.
Composition of Audit Committee

As per requirements of BSEC circular, The Board of Directors of Advent Pharma Limited formed an Audit Committee
headed by Company’s Independent Director Mr. Mohammed Salim, MBA, FCMA. The Committee is composed of 3
(three) members of the Board. The members of the Audit Committee are as follows:
Audit Committee
Mr. Sheikh Karimuzzaman Member
Mr. Asif Iqbal Chowdhury Member
Md. Ikramul Islam Member Secretary
Company Secretary
Meeting and Attendance

During the year 2018-2019, under review the Audit Committee of Advent Pharma Limited conduct 4 (four) meetings
Audit Meeting Attended by Members
Name Position Meeting Attended
Mr. Mohammed Salim, MBA, FCMA

Independent Director Chairman 4
Mr. Sheikh Karimuzzaman
Independent Director Member 2
Mr. Asif Iqbal Chowdhury Member 4
Md. Ikramul Islam Member Secretary 1
Md. Mohsin Mia Ex-Member Secretary 3
The Role and Responsibilities of the Audit Committee
The Role and Responsibilities of the Audit committee are clearly mentioned in the Compliance of Corporate Govern-
ance Code of Bangladesh Securities and Exchange Commission (BSEC) Notification No. BSEC/CMRRCD/2006-
158/207/Admin/80 dated 3June 2018 condition no 5.5. The key responsibilities of the Audit committee are as follows.
(a) Oversee the financial reporting process;

(b) monitor choice of accounting policies and principles;
(c) monitor Internal Audit and Compliance process to ensure that it is adequately resourced, including approval of the
Internal Audit and Compliance Plan and review of the Internal Audit and Compliance Report;
(d) oversee hiring and performance of external auditors;
(e) hold meeting with the external or statutory auditors for review of the annual financial statements before submission
to the Board for approval or adoption;
Annual Report - 42
(f) review along with the management, the annual financial statements before submission to the Board for approval;
(g) review along with the management, the quarterly and half yearly financial statements before submission to the
Board for approval;
(h) review the adequacy of internal audit function;
(i) review the Management’s Discussion and Analysis before disclosing in the Annual Report;
(j) review statement of all related party transactions submitted by the management;
(k) review Management Letters or Letter of Internal Control weakness issued by statutory auditors;
(l) oversee the determination of audit fees based on scope and magnitude, level of expertise deployed and time
required for effective audit and evaluate the performance of external auditors; and
(m) oversee whether the proceeds raised through Initial Public Offering (IPO) or Repeat Public Offering (RPO) or Rights
Share Offer have been utilized as per the purposes stated in relevant offer document or prospectus approved by
the Commission: Provided that the management shall disclose to the Audit Committee about the uses or applications
of the proceeds by major category (capital expenditure, sales and marketing expenses, working capital, etc.), on a
quarterly basis, as a part of their quarterly declaration of financial results: Provided further that on an annual basis,
the company shall prepare a statement of the proceeds utilized for the purposes other than those stated in the offer
document or prospectus for publication in the Annual Report along with the comments of the Audit Committee.
The Committee during the period under report met four times and its activities includes the followings:
• The financial statements of the quarterly, half yearly and the full year were reviewed by the committee and subsequently
recommended to the Board for adoption consideration and circulation as per the requirement of Bangladesh Securities
& Exchange Commission.
• The committee also reviewed the audited financial statements of the Company for the year ended June 30, 2019
this reviews incorporated the accounting policies and key judgments and estimates underpinning financial state-
ments as disclosed in Notes to the Accounts.
• The committee also reviewed the work of the internal audit department and made suggestionsfor improvement.
• The committee reviewed the compliance with existing laws and regulations.
• Approved the internal audit plan.
• Reviewed the effectiveness and independence of the Statuary auditors and recommended re-appointment of external auditors.
Sd/-
On behalf of the Committee
Chairman, Audit Committee
Annual Report - 43
Nomination and Remuneration Committee Report (for
the year ended 30June 2019)
Dear Shareholders,
The Company has formed a Nomination and Remuneration Committee (NRC) as per notification no.
BSEC/CMRRCD/2006-158/207/Admin/80 Dated 3 June 2018.
Members of NRC:
The committee consists of 3 (Three) members; which is as follows:
1. Mr. Mohammed Salim, MBA, FCMA Chairman
(Independent Director)
2. Mr. A.K.M ShafiqulAlam Member
(Nominee Director of Blue Agro Tec Ltd.)
3. Mr. MohammadTowhidul Islam Member
4. Md. Ikramul Islam Member Secretary
The main role of the Committee is to assist and advice the Board on the Company’s remuneration policy for the Board
and Key management personnel, drive diversity and inclusion in the organization, guide standards of behavior and
culture code, ensure appropriate process for performance-related pay in order to motivate and retain executives and
ensure that the company is able to attract the best talent in the market in order to maximize shareholder value.
During the year 2018-2019, the Committee held 1(One) meeting, complying with the requirement of at least one meet-
ing to be held during the year.
NRC Meeting Attendance record of the Members
Name Position Meeting Attended

Chairman 1
Mr. A.K.M ShafiqulAlam(Nominee Director of Blue Agro Tec Ltd.) Member 1
Mr. Mohammad Towhidul Islam
Member 1
Md. Ikramul Islam Member Secretary 1
Terms of Reference:
The terms of reference of the committee as set out by the Nomination and Remuneration Committee which was
adopted by the Board during the year under review. The committee shall oversee, among others, the following matters
and shall recommend the following for review and/or approval of the Board, as the case may be:
i. the criteria for determining qualifications, positive attributes and independence of a director
ii. a policy relating to the remuneration of the directors, top level executive, considering the following:
a. the level and composition of remuneration is reasonable and sufficient to attract, retain and motivate suitable directors
to run the company successfully;
b. the relationship of remuneration to performance is clear and meets appropriate performance benchmarks; and
c. remuneration to directors, top level executive involves a balance between fixed and incentive pay reflecting short
and long-term performance objectives appropriate to the working of the company and its goals;
iii. a policy on Board’s diversity taking into consideration age, gender, experience, ethnicity, educational background
Annual Report - 44
iv. the plan in relation to identification of persons who are qualified to become directors and who may be appointed in
top level executive position in accordance with the criteria laid down, and recommend their appointment and
removal to the Board;
v. the criteria for evaluation of performance of independent directors and the Board;
vi. the plan or proposal on company’s needs for employees at different levels and the selection, transfer or replacement
and promotion criteria/ principles; and
vii. the annual exercise on the developments, recommendations and review of the company’s human resources and
training policies;
Major Activities during the year:

During the year under review, the Committee carried out the following activities:
a. Reviewed and ratified the uniform Code of Conduct for the Company which would is also applicable to members
of the Board and key management personnel or top-level executives which was adopted by the Board
b. Reviewed the available document of the Company which underlies all aspects of individual and collective performance
and functioning of the Company
c. Reviewed the core human resources principles and philosophy of the Company including recruitment, performance
evaluation across all levels of members and talent value proposition of the Company
The NRC Committee expressed their sincere thanks to the members of the Board and Management of the Company
for their support in carrying out its duties and responsibilities effectively. The Committee will proceed to function by
adopting and adhering to a calendar or plan for the year and monitor progress on the same.
On behalf of the Committee
Mohammed Salim, MBA, FCMA

Chairman
Nomination and Remuneration Committe
Annual Report - 45
Credit Rating
Advent Pharma Limited has been rated as BBB+ (Pronounced as Triple B Plus) long term credit rating and ST-3 Short
term credit rating by Alpha Credit Rating Limited based on audited financial statements up to 30 June, 2019, Bank
liability position as on 11 November, 2019 and other available information up to the date of rating declaration. The date
of rating was on 21 November, 2019. The outlook on the rating is Stable.
Long Term Rating Short Term Rating Outlook Date of Validity

BBB+ ST-3 Stable 20 November, 2020
Alpha Credit Rating Limited considered financial performance, scale of business, quality of financial statements and
data presentation, management’s relationship with different parties or stakeholders’ of the business, managements’
business experience and other qualitative factors, increased revenue & profitability, good ROA & ROE, adequate
finance cost payment ability, positive CRO, increasing net asset value, good control efficiency, audit report, low depend-
ency on external facilities, most of the updated compliances, sound liquidity position, good working capital manage-
ment, improved cash conversion cycle, sufficient collateral coverage, efficient managerial effort of the directors while
assigning the rating that reflects the strengths of the company which has long operating history, moderate to high
revenue growth.
Application of International Financial Reporting Stand-

ards (IFRSs) and Internal Accounting Standards (IASs)
Name of the Accounting Standards Ref. No. Status of Application
Presentation of Financial Statements IAS-1 Applied
Inventories IAS-2 Applied
Statement of Cash Flows IAS-7 Applied
Accounting Policies, Changes in Accounting Estimates and Errors IAS-8 Applied
Events after the Reporting Period IAS-10 Applied
Income Taxes IAS-12 Applied
Property, Plant and Equipment IAS-16 Applied
Employee Benefits IAS-19 Applied
Borrowing Costs IAS-23 Applied
Related Party Disclosures IAS-24 Applied
Financial Instruments: Presentation IAS-32 Applied
Earnings Per Share IAS-33 Applied
Impairment of Assets IAS-36 Applied
Provisions, Contingent Liabilities and Contingent Assets IAS-37 Applied
Financial Instruments: Recognition & Measurement IAS-39 Applied
Financial Instruments: Disclosures IFRS-7 Applied
Operating Segments IFRS-8 Applied
Financial Instruments IFRS-9 Applied
Revenue from Contracts with Customers IFRS-15 Applied
Annual Report - 46
Independent Auditors’ Report
To the shareholders of Advent Pharma Limited
Report on the Audit of the Financial Statements
Opinion
We have audited the financial statements of Advent Pharma Ltd (“the Company”), which comprise the Statement of
Financial Position as at 30 June 2019, and Statement of Profit or Loss and other Comprehensive Income, Statement of
Changes in Equity and Statement of Cash Flows for the year then ended, and notes to the financial statements, includ-
ing a summary of significant accounting policies.
In our opinion, the accompanying financial statements give true and fair view, in all material respects, of the financial
position of the Company as at 30 June 2019, and of its financial performance and its cash flows for the year then ended
in accordance with International Financial Reporting Standards (IFRSs) where practicable, the Companies Act 1994,
the Securities and Exchange Rules 1987 and other applicable laws and regulations.
Basis for Opinion

We conducted our audit in accordance with International Standards on Auditing (ISAs). Our responsibilities under those
standards are further described in the Auditors’ Responsibilities for the Audit of the Financial Statements section of our
report. We are independent of the Company in accordance with the International Ethics Standards Board for Accoun-
tants’ Code of Ethics for Professional Accountants (IESBA code) together with the ethical requirements that are relevant
to our audit of the financial statements in Bangladesh, and we have fulfilled our other ethical responsibilities in accor-
dance with the IESBA Code and the Institute of Chartered Accountants of Bangladesh (ICAB) Bye laws. We believe that
the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.
Key Audit Matters

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the
financial statement of the current period. These matters were addressed in the context of our audit of the financial state-
ments as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.
Risk Our response to the risk
Revenue recognition and measurement
During the year,the Company recognized sales revenue ❑ Our audit procedures included the following to test the
of Tk.601,966,497 with an increase of 52% by Tk. design and operating effectiveness of key control focusingon;
205,918,223as compared with previous year. ❑ Segregation of duties in invoice creation and modification;
The Company mainly sales various types of animal ❑ Timing of revenue recognitionconsidering point of
health care drugs, nutritional supplements and feed recognition;
additives in the form of powder, bolus and liquid Our substantive procedures in relation to the revenue
dosage. recognition and measurement comprises the following:
❑ Obtaining and documenting a thorough understanding
We identified sales revenue as an item of key audit
of the complete procedures followed and controls
matters which required significant audit attention during
performed by the Company from initiation of sales
the audit because there might be a risk that revenue
order to delivery of products and subsequent
might not be recognized and correctly measured in
payment received from customers.
accordance with requirement of IFRS 15: leading to the
possibility of risk of material misstatement. ❑ Inspecting selected sample sales transactions
recognized during the year with source documents
such as contract with customer, sales
order/requisition, delivery challan and VAT challan to
testoccurrence and accuracy of recorded sales
revenue.
❑ Performing reconciliation of sales revenue recognized
during the year with monthly Value Added Tax
returns submitted to VAT authority.
Annual Report - 47
Risk Our response to the risk
❑ Making inquiries of appropriate personnel within the

Company to obtain reasonable explanations for
such significant increase in sales revenue as
compared with last year and corroborate with other
documentary evidence.
❑ Finally assessing the appropriateness and presentation
of disclosure notes with IFRS 15: Revenue from
contracts with customers.
See note no. 3.06 to the financial statements
Measurement of current year income tax and deferred tax
During the year, the Company recognized current year Our audit responses adopted during the audit to address
income tax of Tk. 29,817,062 and deferred tax Tk. the risk identified comprise the following:
23,739,905 respectively in the statement of profit or loss
❑ Obtained and documented management procedures
and other comprehensive income. Both of these expenses
involved in determining both current year income tax
have increased significantly compared to corresponding
and deferred tax.
expense recognized in the last year.
❑ Obtained understanding and reviewed relevant section
Determination of both current year income tax and of the ITO and SRO to test the accuracy of rate applied
deferred tax involves compliance with the Income Tax by the Company.
Ordinance (ITO) 1984 and latest finance act along with IAS
❑ Reviewed rate of depreciation used in determining tax
12: Income Tax, there is a higher risk of material misstate-
depreciation in compliance with the latest finance act
ment that amount charged in profit or loss might be
which is used to determine taxable profit and deferred
over/understated.
tax.
❑ Re-performed detailed calculation of current year
income tax and deferred tax as given by the Company.
❑ Inspected latest assessment order completed and
compared amount of tax paid by the Company with
amount recognized in the financial statements.
See note no. 3.16 to the financial statements
Other Information
Management is responsible for the other information. The other information comprises all of the information in the
annual report other than the financial statements and our auditor’s report thereon. The directors are responsible for the
other information.
Our opinion on the financial statements does not cover the other information and we do not express any form of assur-
ance conclusion thereon.
In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing
so, consider whether the other information is materially inconsistent with the financial statements or our knowledge
obtained in the audit or otherwise appears to be materially misstated. If, based on the work we have performed, we
conclude that there is a material misstatement of this other information we are required to report that fact. We have
nothing to report in this regard.
Responsibilities of Management and Those Charged with Governance for the Financial Statements and Inter-
nal Controls
Management is responsible for the preparation and fair presentation of the financial statements in accordance with
IFRSs, the Companies Act 1994, the Securities and Exchange Rules 1987 and other applicable laws and regulations
and for such internal control as management determines is necessary to enable the preparation of financial statements
that are free from material misstatement, whether due to fraud or error. The companies Act, 1994 require the manage-
ment to ensure effective internal audit, internal control and risk management factions of the company.
Annual Report - 48
In preparing the financial statements , management is responsible for assessing the company’s ability to continue as a
going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of
accounting unless management either intends to liquidate the company or to cease operations, or has no realistic
alternative but to do so.
Those charged with governance are responsible for overseeing the Company’s financial reporting process.
Auditors’ Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from
material misstatement, whether due to fraud or error, and to issue an auditor’s report that includes our opinion. Reason-
able assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs will
always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered
material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of
users taken on the basis of these financial statements.
As part of an audit in accordance with ISAs, we exercise professional judgment and maintain professional skepticism
throughout the audit. We also:
• Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error,
design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and
appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud
is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepre-
sentations, or the override of internal control.
• Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appro
priate in circumstances.
• Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and
related disclosures made by management.
• Conclude on the appropriateness of management’s use of the going concern basis accounting and, based on the
audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast signifi-
cant doubt on the Company’s ability to continue as a going concern. If we conclude that a material uncertainty
exists, we are required to draw attention in our auditors’ report to the related disclosures in the financial statements
or, if such disclosers are inadequate, to modify our opinion. Our conclusions are based on the audit evidence
obtained up to the date of our auditors’ report. However, future events or conditions may cause the company to
cease to continue as a going concern.
• Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and
whether the financial statements represent the underlying transactions and event in a manner that achieves fair
presentation.
• Obtain sufficient appropriate audit evidence regarding the financial information of the entities or business activities
within the group to express an opinion on the financial statement we are responsible for the direction, supervision
and performance of the group audit. We solely responsible for our audit opinion.
We communicate with those charged with governance regarding, among other matters, the planned scope and timing
of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.
We also provide those charged with governance with a statement that we have complied with relevant ethical require-
ments regarding independence, and communicate with them all relationships and other matters that may reasonably
be thought to bear on our independence, and where applicable, related safeguards.
From the matters communicated with those charged with governance, we determine those matters that were of most
significance in the audit of the financial statements of the current period and are therefore the key audit matters. We
describe these matters in our auditor’s report unless law or regulation precludes public disclosure about the matter or
when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because
the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such
communication.
Annual Report - 49
Report on Other Legal and Regulatory Requirements
In accordance with the Companies Act 1994, and the Securities and Exchange Rules 1987 and relevant notifications
issued by Bangladesh Securities and Exchange Commission, we also report that:
a) We have obtained all the information and explanations which to the best of our knowledge and belief were
necessary for the purpose of our audit and made due verification thereof;
b) In our opinion, proper books of accounts, records and other statutory books as required by law have been kept
by the Company so far as it appeared from our examinations of those books;
c) The Statement of Financial Position, Statement of Profit or Loss and Other Comprehensive Income of the
Company dealt with by the report are in agreement with the books of account and returns;
d) The expenditures incurred were for the purpose of the Company’s business.
Place: Dhaka Sd/-

Dated: 27 October, 2019 Ahmed Zaker & Co.
Chartered Accountants
Annual Report - 50
Advent Pharma Ltd.
Statement of Financial Position
As at June 30, 2019
Amount in Taka
Particulars Notes
30-June-2019 30-June-2018
ASSETS
NON-CURRENT ASSETS 931,180,917 685,286,322
Property, Plant and Equipment 4.00 844,729,863 590,552,956
Capital Work in Progress (Building Construction) 5.00 86,451,054 94,733,366
CURRENT ASSETS 276,465,072 327,475,163

Inventories 6.00 70,810,152 63,681,683
Trade and Other Receivable 7.00 78,850,747 52,017,501
Advances, Deposits and Pre-payments 8.00 38,061,290 25,382,166
Cash and Cash Equivalents 9.00 88,742,883 186,393,813
Total Assets 1,207,645,989 1,012,761,485
SHAREHOLDERS' EQUITY AND LIABILITIES

SHAREHOLDERS' EQUITY 1,018,634,442 873,950,804
Share Capital 10.00 754,600,000 686,000,000
Retained Earnings 11.00 264,034,442 187,950,804
NON-CURRENT LIABILITIES 86,113,884 66,713,929

Long Term Borrowings - Net of Current Portion 12.00 19,114,798 23,454,748
Deferred Tax Liabilities 14.00 66,999,086 43,259,181
CURRENT LIABILITIES 102,897,663 72,096,752

Current Portion of Long Term Borrowings 12.00 7,912,963 7,912,963
Payable to IPO Applicants 129,355 424,390
Short Term Borrowings 13.00 7,235,622 20,182,773
Trade and other payables 15.00 12,630,812 4,323,753
Liabilities for expenses 16.00 4,083,317 4,031,820
Liability for contribution to WPPF 17.00 11,982,914 6,115,435
Provision for Current Tax 18.00 58,922,680 29,105,618
Total Liabilities 189,011,547 138,810,681

Total Shareholders' Equity and Liabilities 1,207,645,989 1,012,761,485
Net Asset Value (NAV) per Share 27.00 13.50 12.74
The accounting policies and explanatory notes are an integral part of the Financial Statements.
Sd/- Sd/- Sd/- Sd/-

Company Secretary Chief Financial Officer Managing Director Chairman
Signed in terms of our separate report of even date annexed.
Sd/-
Dated: October 27, 2019 Ahmed Zaker & Co.
Place: Dhaka Chartered Accountants
Annual Report - 51
Advent Pharma Ltd.
Statement of Profit or Loss and Other Comprehensive Income
For the year ended June 30, 2019
Amount in Taka
Particulars Notes
2018 - 2019 2017 - 2018
Revenues 19.00 601,966,497 396,048,274
Cost of Sales 20.00 (318,146,576) (222,515,836)
Gross Profit 283,819,921 173,532,438
Operating Expenses (60,793,009) (71,475,335)

Administrative expenses 21.00 (24,502,073) (25,223,079)
Selling & Marketing Expenses 22.00 (36,290,936) (46,252,256)
Operating Profit 223,026,912 102,057,103
Non Operating Expenses (5,741,191) (5,749,880)

Financial Expenses 23.00 (5,741,191) (5,749,880)
Other Income 24.00 6,935,771 3,034,356
Loss on disposal on Fixed Assets 25.00 (1,662,857) -
Profit Before W.P.P.F 222,558,635 99,341,579
Expenses for W.P.P.F 17.00 (10,598,030) (4,730,551)
Profit Before Tax 211,960,605 94,611,028
Income Tax Expenses (53,556,967) (7,733,996)

Current Tax 18.00 (29,817,062) (4,266,964)
Deferred Tax Expenses 14.00 (23,739,905) (3,467,032)
Net Profit After Tax 158,403,638 86,877,032
Other Comprehensive Income - -

Total Comprehensive income 158,403,638 86,877,032
Earnings per Share (EPS) 26.00 2.10 1.41
The accounting policies and explanatory notes are an integral part of the Financial Statements.
Sd/- Sd/- Sd/- Sd/-

Signed in terms of our separate report of even date annexed.
Sd/-
Annual Report - 52
Advent Pharma Ltd.
Statement of Changes in Equity
Ordinary Share Retained

Particulars Total
Capital Earnings
Balance as on July 01, 2018 686,000,000 187,950,804 873,950,804

Net Profit for the year - 158,403,638 158,403,638
Stock Dividend (2017-2018) 68,600,000 (68,600,000) -
Cash Dividend (2017-2018) - (13,720,000) (13,720,000)
Balance as on June 30, 2019 754,600,000 264,034,442 1,018,634,442
Advent Pharma Ltd.

Statement of Changes in Equity
Ordinary Share Retained

Particulars Total
Capital Earnings
Balance as on July 01, 2017 486,000,000 119,272,077 605,272,077

New share Issued Through IPO 200,000,000 - 200,000,000
Net Profit for the year - 86,877,032 86,877,032
Adjustment for IPO Expenses - (18,198,305) (18,198,305)
Balance as on June 30, 2018 686,000,000 187,950,804 873,950,804
Sd/- Sd/- Sd/- Sd/-

Sd/-
Annual Report - 53
Advent Pharma Ltd.
Statement of Cash Flows
Particulars Amount in Taka

2018 - 2019 2017 - 2018
A. CASH FLOWS FROM OPERATING ACTIVITIES:
Cash Receipts from Customers & Others 582,069,022 393,643,837

Cash Paid to Suppliers (286,209,895) (187,578,748)
Cash paid to Employees (43,536,757) (47,982,268)
Cash paid to Others (35,849,097) (43,906,230)
Tax Paid During This Year (11,920,491) (4,021,149)
Net cash generated from operating activities 204,552,782 110,155,442
B. CASH FLOWS FROM INVESTING ACTIVITIES:

Paid for Acquisition of Property, Plant & Equipment (185,990,007) (4,956,721)
Paid for Capital Work -in- Progress (construction) (87,276,054) (141,898,491)
LC Margin for Machineries (80,906) -
Proceeds from disposal of Fixed Assets 250,767 -
Net cash used for investing activities (273,096,200) (146,855,212)
C. CASH FLOWS FROM FINANCING ACTIVITIES:

Short Term Borrowings- Received/(Payment) (12,947,151) 10,181,186
Long Term Borrowings-Received/(Payment) (4,339,950) (3,086,650)
Financial Expenses Paid (6,054,194) (5,758,552)
IPO Expenses - (18,198,305)
Cash Dividend Paid (5,471,182) -
Issuance of Share Capital - 200,000,000
Proceeds from IPO applicant-Refundable (295,035) 424,390
Net cash used for financing activities (29,107,512) 183,562,069
D. Net Increase/(Decrease) in cash & cash equivalents (A+B+C) (97,650,930) 146,862,299

E. Cash & Cash equivalents at the beginning of the year 186,393,813 39,531,514
F. Cash & Cash equivalents at the end of the year (D+E) 88,742,883 186,393,813
G. Net Operating Cash Flows Per Share 2.71 1.79
Sd/- Sd/- Sd/- Sd/-

"Signed in terms of our separate report of even date annexed"
Sd/-
Annual Report - 54
Notes, comprising a summary of significant accounting policies and other explanatory information
as at and for the year ended 30 June-2019
1.00 Corporate History of the Reporting Entity

Advent Pharma Limited (The Company) was incorporated in Bangladesh as a Private Limited Company under
the Companies Act, 1994 vide Registration No. C-65459(2951)/2007 dated 25th January, 2007. Subsequently
the company was converted into Public Company Limited by share on 07 May, 2016. Register address of the
company: Rupayan karim Tower, Level-10, 80, Kakrail VIP Road, Ramna, Dhaka-1000.
2.00 Corporate Business

The Company is a Pharmaceutical company which is engaged in manufacturing, importing and marketing of
animal health care drugs, nutritional supplements and feed additives for livestock like powder, bolus and liquid
dosage forms. All products have duly been approved by Drug Administration Authority and Department of Live
Stock respectively.
3.00 Basis of preparation and significant accounting policies

3.01 Basis of Measurement of Elements of Financial Position
The financial statements of the company have been prepared on going concern assumption under historical cost
convention, on accrual basis and in accordance with the International Accounting Standards (IASs), International
Financial Reporting Standards (IFRSs), the Companies Act 1994, the Securities Exchange Rules 1987 and other
laws and regulations applicable for the company.
The following International Accounting Standards (IASs) were applied for the preparation of the financial state
ments for the year.
IAS-1 Presentation of Financial Statements
IAS-2 Inventories
IAS-7 Statement of Cash Flows
IAS-8 Accounting Policies, Changes in Accounting Estimates and Errors
IAS-10 Events after the Reporting Period
IAS-12 Income Taxes
IAS-16 Property, Plant and Equipment
IAS-19 Employee Benefits
IAS-23 Borrowing Costs
IAS-24 Related Party Disclosures
IAS-32 Financial Instruments: Presentation
IAS-33 Earnings per Share
IAS-36 Impairment of Assets
IAS-37 Provisions, Contingent Liabilities and Contingent Assets
IAS-39 Financial Instruments: Recognition and Measurement
IFRS-7 Financial Instruments: Disclosures
IFRS-8 Operating Segments
IFRS-9 Financial Instruments
IFRS-15 Revenue from Contracts with Customers
3.02 Going Concern Assumption

The company has adequate resources to continue its operation for the foreseeable future. As such, the directors
intended to adopt the going concern basis in preparing the financial statements. The current credit facilities and
resources of the company provides sufficient fund to meet the present requirements of its existing business.
Annual Report - 55
3.03 Structure, Content and Presentation of Financial Statements
Being the general purpose of financial statements, the presentation of these financial statements is in accord
ance with the guidelines provided by IAS-1 Presentation of Financial Statements. The financial statements
comprises the followings;
i) Statement of Financial Position as at June 30, 2019;
ii) Statement of Profit or Loss and Other Comprehensive Income for the year ended June 30, 2019;
iii) Statement of Changes in Equity for the year ended June 30, 2019;
iv) Statement of Cash Flows for the year ended June 30, 2019;
v) Notes, comprising a summary of significant accounting policies and other explanatory information as at and
for the year ended June 30, 2019.
3.04 Reporting Currency and level of precision

The figure in the financial statements has been presented in Bangladesh Taka Currency and has been Rounded
off to the nearest Taka where necessary.
3.05 Reporting Period

The period of the financial statements covers 12(Twelve) months from 01 July, 2018 to 30 June, 2019.
3.06 Revenue
"As per IFRS-15: Revenue from Contracts with Customers an entity shall account for a contract with a customer
only when all of the following criteria are met:
(a) The parties to the contract have approved the contract (in
writing , orally or in accordance with other customary business practices) and are committed to perform their
respective obligations ;
(b) The entity can identify each party ‘s rights regarding the goods or services to be trans
ferred ;
(c) The entity can identify the payment terms for the goods or services to be transferred ;(d) The contract
has commercial substance (i.e. the risk , timing or amount of the entity's future cash flows is expected to change
as a result of the contract ); and
(e) It is probable that the entity will collect the consideration to which it will be
entitled in exchange for the goods or services that will be transferred to the customer."
3.07 Property, Plant and Equipment

Initial Recognition and measurement
Property, plant and equipment have been capitalized at cost of acquisition and subsequently stated at cost less
accumulated depreciation in compliance with the requirements of IAS-16 Property, Plant and Equipment. The
cost of acquisition of an asset comprises its import/ purchase price including non refundable duty taxes and any
other directly attributable incidental cost of bringing the assets for its intended use.
Depreciation on Fixed Assets

In accordance with the provisions of IAS-16 Property, Plant and Equipment. Depreciation charged on an asset
when the assets are available for use. Depreciation is charged on all fixed assets on reducing balance method.
The Rate of depreciation for this year as below:
Annual Report - 56
Particulars 30-Jun-2019 30-Jun-2018
Land - -
Land Development 2.5% 2.50%
Factory Building 2.5% 2.5%
Plant & Machinery 5% 5%
Sub-Station 10% 10%
Motor Vehicle 15% 15%
Furniture & Fixture 10% 10%
Solar Panel 10% 10%
Generator 10% 10%
Air Conditioner 5% 5%
Office Equipment 10% 10%
HVAC System 5% 5%
Laboratory Equipment 5% 5%
Product development Equipment 5% 5%
ETP 5% 5%
Books & Journals 15% 15%
3.08 Cash and Cash equivalents

Cash and cash equivalents comprise cash in hand, demand deposits and short term deposit, highly liquid invest
ments that are readily convertible to known amounts of cash and which are subject to an insignificant risk of
changes in value.
3.09 Inventories
Inventories are carried at the lower of cost or net realizable value as prescribed by IAS-2 Inventories. Cost is
determined on weighted average cost basis. The cost of inventories comprises of expenditure incurred in the
normal course of business in bringing the inventories to their present location and condition. Net realizable value
is based on estimated selling price less any further costs expected to be incurred to make the sale.
3.10 Events after the Reporting Period

Events after the Reporting Period that provide additional information about the companies position at the date of
statement of Financial position are reflected in the Financial Statements. Events after the reporting period that
are non adjusting events are disclosed in the notes when material.
3.11 Statement of Cash Flows

The Statement of Cash Flows is prepared in accordance with International Accounting Standards IAS-7 State
ment of Cash Flows and cash flows from the operating activities have been presented under direct method
considering the provision of paragraph 19 of IAS-7 which provides that "Entities are encouraged to report cash
flows from operating activities using the direct method".
3.12 Related Party Disclosures

The company in normal course of business carried out a number of transactions with related parties that fall
within the definition of related party as prescribed by IAS-24 "Related Party Disclosures". This has been
disclosed in a separate note to the financial statements.
3.13 Earnings Per Share

The company calculates Earnings per Share (EPS) in accordance with the requirement of IAS-33 "Earnings per
Share", which has been shown on the face of the Statement of Profit or Loss and Other Comprehensive Income.
Annual Report - 57
Basic earnings
This represents earnings for the year ended June 30, 2019 attributable to the ordinary shareholders.
Basic earnings per share

This has been calculated dividing the basic earning by the weighted average number of shares outstanding
during the year.
Diluted earnings per share

Diluted EPS is not applicable for these financial statements as there was no potential dilutive ordinary shares
during the year ended 30 June, 2019.
3.14 Impairment of Assets

I) Financial Assets
Accounts receivable and others receivables are assessed at each reporting date to determine whether there is
any objective evidence of impairment. Financial assets are impaired if objective indicates that a loss event has
occurred after the initial recognition of the asset and that the loss event had a negative effect on the estimated
future cash flows of that asset that can be estimated reliably. Objective evidence that financial assets are
impaired can include default of delinquency by a debtor, indicates that a debtor of issuer will enter bankruptcy etc.
II) Non-Financial assets

An asset is impaired when its carrying amount exceeds its recoverable amount. The company assesses at each
reporting date whether there is any indication that an asset may be impaired. If any such indication exits, the
company estimates the recoverable amount of the asset. The recoverable amount of an asset is the higher of its
fair value less cost to sell and its value in use. Carrying amount of the assets is reduced to its recoverable amount
by recognizing an impaired loss is recognized immediately in statement of comprehensive income unless the
asset is carried at revalued amount. Any impaired loss of a revalued asset treated as a revaluation decrease.
All fixed and financial assets have been reviewed and it was confirmed that no such assets have been impaired
during the year and for this reason no provision has been made for impairment of assets.
3.15 Provisions
In accordance with the guidelines as prescribed by IAS-37" Provisions, Contingent Liabilities and Contingent
Assets", provisions are recognized in the following situations when:
a) an entity has an obligation (legal or constructive) as a result of past events;

b) it is probable that an outflow of resources embodying economic benefits will be required to settle the obliga
tion; and
c) a reliable estimates can be made of the amount of the obligation.
3.16 Income Tax

Current Tax
Provision for taxation has been made as per rates prescribed in Finance Act 2019 and the Income Tax
Ordinance, 1984 on the profit made by the company.
Deferred Tax
The company accounts for deferred tax as per International Accounting Standards(IAS)12 Income Taxes.
Deferred Tax is arising due to temporary difference in between carrying amount of book value of assets and
liabilities and its tax base. The tax rate prevailing at the balance sheet date is used to determine deferred tax.
Annual Report - 58
3.17 Workers Profit Participation Fund (WPPF)
The company has created a fund for workers " Workers profit participation fund (WPPF)" as per Bangladesh
Labour Act, 2006 (Amendment 2013) by 5% of profit after charging such expenses.
3.18 VAT
Company Produces both Vatable and Non-Vatable Product. The company paid VAT only on vatable items and
enjoying exemption for non vatable items as per S.R.O No. 172-AIN/2019/29-MUSHUK, dated: June 13, 2019.
3.19 Comparative Information

Comparative information has been disclosed in the respect of previous year for all numeric information in the
financial statements and also the narrative and descriptive information where it is relevant for understanding of
the current year’s financial statement.
3.20 Financial Instruments

A financial instrument is any contract that gives rise to a financial asset to one entity and a financial liability or
equity instrument to another entity as per IAS-39 Financial Instruments: Recognition and Measurement.
Financial Assets
Financial assets of the company include cash and cash equivalents, equity instrument to another entity, Trade
receivables and other receivables. The company initially recognize a financial asset in its statement of finan
cial position when, and only when, the company becomes a party to the contractual provision of the instrument.
The company derecognize a financial asset when, and only when; the contractual rights to the cash flows from
the financial asset expire or transfer the contractual rights to receive the cash flows of the financial asset.
Financial Liabilities
"The company initially recognize a financial liability in its statement of financial position when, and only when,
the company becomes a party to the contractual provision of the instrument. The company derecognize a finan
cial liability from its statement of financial position when, and only when, it is extinguished, that is when the
obligation specified in the contract is discharged or cancelled or expires. "
3.21 Employee Benefits

The company maintains defined benefit plan for its eligible permanent employees. The eligibility is determined
according to the terms and conditions set delineated in the respective deeds. The company has accounted for
and disclosed employees benefits in compliance with the provisions of IAS 19 Employee Benefits. The cost of
employee benefit is charged off as revenue expenditure in the period to which the contributions relate.
The Company's employee benefits include the following:
Short Term Employee Benefits

Short term employee benefits include salaries, bonuses etc. Obligations for such benefits are measured on an
undiscontinued basis are expensed as the related service is provided.
Annual Report - 59
Worker's profit participation fund(WPPF)
The company recognized WPPF at the rate of 5% on profit after charging such expenses before tax and payment
is made to the workers as per provisions of Bangladesh Labour Act, 2006 (Amendment 2013).
3.22 Operating Segments:

"As required by IFRS-8 Operating Segment, if an entity operates business activities that may earn revenues or
incur expenses, whose operating results are regularly reviewed by the chief operating decision maker and for which
discrete financial information is available. The company consider the operation on aggregate basis and manage the
operations as a single operating segment. Hence it is felt that such segment reporting is not required to be
disclosed."
3.23 Risk Management:

The management of the company is overall responsible for the establishment and oversight of the company's risk
management framework. Risk management policies, procedures and systems are reviewed regularly to reflect
changes in market conditions and the company's activities. The company has exposure to the following risk for its
use of financial instrument.
Credit Risk
Liquidity Risk
Market Risk
Credit Risk:
Credit risk is the risk of a financial loss to the company if a customer or counterparty to a financial instrument fails
to meet its contractual obligations and arises principally from the company's receivables. As at 30 June, 2019 there
has no credit risk against receivables.
Management perception:
To mitigate the the credit risk the management of the company follows robust credit control and collection polices.
The company has dedicated credit collection team who are responsible for any dues and they have been demon
strating remarkable performance in collecting receivables as per company's credit and collection policy.
Liquidity Risk:
Liquidity risk is defined as the risk that the company will not be able to settle or meet its financial obligations on time
or at a reasonable price.
The company's approach to managing liquidity is to ensure, as far as possible, that it will always have sufficient
liquidity to meet its liabilities when due, under both normal and stressed conditions, without incurring unacceptable
losses or risking damage to the company's reputation. Typically, management ensures that it has sufficient cash
and cash equivalent to meet expected operational expenses, including the servicing of financial obligation
through preparation of the cash forecast, prepared based on time line of payment of the financial obligation and
accordingly arrange for sufficient liquidity/ fund to make the expected payment within due date.
Market Risk:
Market Risk:
Market risk is refers to the risk of adverse market conditions affecting the sales and profitability of the company.
Mostly, the risk arises from falling demand for the product or service which would harm the performance of the
company. On the other hand, strong marketing and brand management would help the company increase their
customer base.
Management is fully aware of the market risk, and act accordingly. Market of animal health products in Bangla
desh is growing rapidly. Moreover the company has a strong marketing and brand management to increase the
customer base and customer loyalty.
3.24 Authorisation for issue

The financial statements were authorized for issue by the Board of Directors of the company on 27 October,
2019.
Annual Report - 60
Amount in Taka
30-June-2019 30-June-2018
4.00 Property, Plant and Equipment
A. Cost
Opening Balance 648,882,223 536,897,629
Add: Addition during the year 280,723,373 111,984,594
Less: Disposal during the year (2,190,000) -
927,415,596 648,882,223
B. Accumulated Depreciation
Opening Balance 58,329,267 34,166,241
Add: Depreciation charged during the year 24,632,842 24,163,026
Less: Adjustment during the year (276,376) -
82,685,733 58,329,267
Written down Value (A-B) 844,729,863 590,552,956
Details are shown in Annexure-A.
5.00 Capital Work In Progress (Building Construction)

Opening Balance 94,733,366 59,334,748
Addition during the year 240,757,598 142,426,491
Transfer to Factory Building (249,039,910) (107,027,873)
Closing Balance 86,451,054 94,733,366
6.00 Inventories
Finished Goods( Note-20) 22,786,458 19,265,698
Raw Materials (Note-20.01) 27,308,790 24,398,106
Packing Materials(Note-20.02.01) 6,779,356 5,372,560
Spare Parts (Note-20.02.02) 388,658 370,452
Work In Process (Note-20.00) 13,546,890 14,274,867
70,810,152 63,681,683
Details of Finished goods, Raw Materials and Packing Material has been shown in Annexure-B.
7.00 Trade & Other Receivables 78,850,747 52,017,501

Ageing of Trade Receivable
More than six months - -
Less than six months 78,850,747 52,017,501
78,850,747 52,017,501
The classification of receivables as required by the Schedule XI, Part I, Para 4 of the Companies Act, 1994 are
given below:
Receivables considered good and in respect of which the company is fully

secured. - -
Receivables considered good for which the company holds no security
other than the debtor's personal security. 78,850,747 52,017,501
Receivables considered doubtful or bad. - -
Receivables due by directors or other officers of the company or any of them
either severally or jointly with any other person or receivables due by firms or
private companies respectively in which any director is a partner or a director or - -
Receivables due by companies under the same management. - -
The maximum amount due by directors or other officer of the company at any
time during the year. - -
Total 78,850,747 52,017,501
Annual Report - 61
Amount in Taka
30-June-2019 30-June-2018
8.00 Advances, Deposits & Pre-payments
Advances (Note - 8.01) 34,831,299 21,949,355
Deposits (Note - 8.02) 1,129,724 1,019,724
Prepayments (Note - 8.03) 25,260 25,260
VAT Current Account 2,075,007 2,387,827
38,061,290 25,382,166
8.01 Advances
Advance against Tax (8.01.01) 33,788,346 21,867,855
Advance against Salary 35,000 81,500
Advance against Construction 825,000 -
Advance against Raw Materials 102,047 -
Advance LC Margin for Machinery 80,906 -
34,831,299 21,949,355
8.01.01 Advance against Tax

Opening Balance 21,867,855 17,846,706
Add: Paid During the year (Note-8.01.02) 11,920,491 4,021,149
33,788,346 21,867,855
8.01.02 Tax paid during the year
For the Income year 2013 237,000 -
For the Income year 2016-2017 - 2,694,100
For the Income year 2017-2018 1,283,361 -
Others 9,842,130 1,327,049
Total 11,920,491 4,021,149
8.02 Deposits
Security Deposit - Electricity 550,424 550,424
Security Deposit -Titas Gas Transmission & Distribution Co. Ltd. 83,000 183,000
Security against-House Rent 391,000 282,000
Security Deposit -BTCL. 5,300 4,300
1,129,724 1,019,724
8.03 Prepayments
Prepaid Fire Insurance:
Opening Balance 25,260 25,260
Add: Advance paid during the year 101,049 101,049
Less: Charged during the year (101,049) (101,049)
Closing Balance 25,260 25,260
9.00 Cash & Cash Equivalents

Cash in hand (Note-9.01) 231,781 159,859
Cash at bank (Note-9.02) 88,511,102 186,233,954
Total 88,742,883 186,393,813
9.01 Cash in Hand

Head Office 207,370 132,043
Depots 24,411 27,816
231,781 159,859
Cash in hand has been certified by the management of the company.
Annual Report - 62
Amount in Taka
30-June-2019 30-June-2018
9.02 Cash at Bank 88,511,102 186,233,954

9.02.01 Cash at Bank
Bank Name Branch Name
Islami Bank Bangladesh Ltd., New Market Branch 72,830 15,879
Dutch Bangla Bank Ltd. Satmosjid Road 1,134,212 303,861
Janata Bank Ltd. Dhanmondi Branch 173,198 58,282
IFIC Bank Ltd. Dhanmondi Branch 5,338,665 4,309,764
IFIC Bank Ltd. Dhanmondi Branch 1,275,496 2,209,841
IFIC Bank Ltd. Dhanmondi Branch 126,750 -
Midland Bank Ltd. Dilkusha Branch 165,794 -
BRAC Bank Ltd. Gulshan Branch 91,149 163,821,424
BRAC Bank Ltd. Gulshan Branch 104,122 424,390
Shahjalal Islami Bank Ltd. Satmosjid Road 28,885 90,512
Total 8,511,102 171,233,954
9.02.02 Fixed Deposit Receipt (FDR):

Name of Financial Institution
IFIC Bank Ltd. -FDR No # 1299816 - 15,000,000
Midland Bank Ltd. - FDR No # 0019761 40,000,000 -
Phoenix Finance & Investment - TDR No # 23977/18 30,000,000 -
IFIC Bank Ltd. -FDR No # 1299962 10,000,000 -
Total 80,000,000 15,000,000
10.00 Share Capital

Authorized Capital :
100,000,000 ordinary shares of Tk. 10.00 each 1,000,000,000 1,000,000,000
Issued, Subscribed & Paid-up Capital :
668,60,000 ordinary shares of Tk. 10.00 each 754,600,000 686,000,000
754,60,000 ordinary shares of Tk. 10.00 each
Share holding position of Shareholders:
Category of Share No. of Share Holding Percentage of Share Amount in Taka

Holders 30-Jun-2019 30-Jun-2019 30-Jun-2019 30-Jun-2018
Director & Sponsor 23,724,250 31.44% 237,242,500 215,675,000
Institutional 14,920,238 19.77% 149,202,380 144,150,000
Public 36,815,512 48.79% 368,155,120 326,175,000
TOTAL 75,460,000 100% 754,600,000 686,000,000
The distribution schedule showing the number of shareholders and their share holdings in percentage
has been disclosed below:
Annual Report - 63
As per Folio As per BOID
Range of Share No. of No. of Total Share
%
Holdings Holders Holdings Holders Holdings Holdings
Up to 500 Shares - - 1,360 234,679 234,679 0.311
501 to 5,000 Shares - - 1,905 3,253,860 3,253,860 4.312
5,001 to 10,000 Shares - - 334 2,591,077 2,591,077 3.434
10,001 to 20,000 Shares - - 195 2,893,152 2,893,152 3.834
20,001 to 30,000 Shares - - 76 1,933,284 1,933,284 2.562
30,001 to 40,000 Shares - - 26 911,949 911,949 1.209
40,001 to 50,000 Shares - - 28 1,329,749 1,329,749 1.762
50,001 to 100,000 Shares - - 55 4,011,085 4,011,085 5.316
100,001 to 1,000,000 Shares - - 78 23,201,147 23,201,147 30.746
Over 1,000,000 Shares 1.00 1,540,000 14 33,560,018 35,100,018 46.515
Total 1.00 1,540,000 4,071 73,920,000 75,460,000 100.000
Amount in Taka
30-June-2019 30-June-2018
11.00 Retained Earnings
Balance brought forward 187,950,804 119,272,077
Add: Profit for the year 158,403,638 86,877,032
Adjustment for IPO Expenses - (18,198,305)
Stock Dividend (68,600,000) -
Cash Dividend (13,720,000) -
Balance carried forward 264,034,442 187,950,804
12.00 Long Term Borrowings Net of Current Portion

Islami Bank Bangladesh Ltd., New Market Branch. 21,278,375 24,410,107
Islami Bank Bangladesh Ltd., New Market Branch. 6,050,313 7,065,903
Total 27,328,688 31,476,010
Less: Current Portion of long Term loan (7,912,963) (7,912,963)
Less: Accrued Interest on Long Term Loan (300,927) (108,299)
Net Amount 19,114,798 23,454,748
Terms and conditions

This represent the present outstanding balance of the above Long term loans(Project Loan) taken for Construc
tion Works and purchase of Machinery. The above loans are secured by land with building and Existing Machin
ery. The rate of interest of this loans are varying from 11% -15%.
Annual Report - 64
Amount in Taka
30-June-2019 30-June-2018
13.00 Short Term Borrowings
Islami Bank Bangladesh Ltd., New Market Branch - 1,600,966
Islami Bank Bangladesh Ltd., New Market Branch - 504,082
IFIC Bank Ltd. Dhanmondi Branch - 13,608,000
Midland Bank Ltd., Dilkusha Branch 796,034 -
Midland Bank Ltd., Dilkusha Branch 1,859,467 -
Total Amount 7,457,752 20,910,534

Less: Accrued Interest on Short Term Loan (222,130) (727,761)
Net Amount 7,235,622 20,182,773
Terms and conditions

This represent the present outstanding balance of the above short term loans(working capital Loan) taken for
purchase of Raw materials. The above loans are secured by land with building and Existing Machinery. The
rate of interest of this loans are varying from 11% -15%.
14.00 Deferred Tax Liabilities

Opening Balance 43,259,181 39,792,149
Add: Provision made during the year (Note-14.01) 23,739,905 3,467,032
Closing Balance 66,999,086 43,259,181
14.01 Deferred tax liabilities as at June 30, 2019 is arrived as follows :

Written Down Value of PPE as per Accounting Base 844,729,863 590,552,956
Adjustment of WPPF (11,982,914) (6,115,435)
Written Down Value Considering WPPF 832,746,948 584,437,520
Written Down Value as per Third Schedule (564,750,605) (411,400,796)
Net Temporary Difference 267,996,343 173,036,724
Income Tax Rate 25% 25%
Closing Deferred Tax Liability 66,999,086 43,259,181
Opening Deferred Tax Liability (43,259,181) (39,792,149)
Deferred Tax Expenses 23,739,905 3,467,032
Annual Report -65

Amount in Taka
30-June-2019 30-June-2018
15.00 Trade and other payables

Chemi Trade 1,383,150 1,384,268
Mars Trading 938,000 1,000,700
Annex International - 124,500
AR Plastic Industries 84,674 242,317
Asia Plastic Container 41,500 325,778
Digital Sign Pack 623,147 553,983
Free Mason International 10,830
Jamuna Corporation 40,700 -
Medi Graphic Trading Ltd. - 65,000
Metro Foils Ltd. - 59,060
Moon International 7,200
M/S Siyam Enterprise 330,000 -
M/S Shefa Trading 131,940 -
M/S Sonali Center Pvt. Ltd. 22,447
New Progressive Traders 53,220
Pakeza Graphics & Design & Printing 86,700 234,620
Paradise Scientific Company - 99,500
Pharmalink Engineering Technology 90,000 -
Ripon Works Motor 50,260 -
Sky Foils Ltd. 95,667 59,990
S.M. Enterprise 152,884 -
South Packmart Ltd. - 50,700
Total Can & Closer Ltd. 39,675 123,337
Cash Dividend Payable 8,248,818 -
Total 12,630,812 4,323,753
This outstanding liabilities are payable to the parties who supplied goods and rendered services to the
company.
16.00 Liabilities for expenses

Electricity Bill 236,101 137,064
Salary and Wages 2,905,162 2,652,520
Director Remuneration 97,000 100,000
Telephone & Mobile bill 1,657 1,256
Accrued Interest (Note-16.01) 523,057 836,060
TDS Payable 12,840 17,420
Office Rent 57,500 57,500
Audit Fees 230,000 230,000
Legal, License, Renewals & Professional fee 20,000 -
Total 4,083,317 4,031,820
16.01 Accrued Interest on Loan

Accrued Interest on Long Term Loan (Note-16.01.01) 300,927 108,299
Accrued Interest on Short Term Loan (Note-16.01.02) 222,130 727,761
Total Amount 523,057 836,060
Annual Report - 66
Amount in Taka
30-June-2019 30-June-2018
16.01.01 Accrued Interest on Long Term Loan
Interest Charged during the year 3,943,278 4,120,709
Payment made during the year (3,750,650) (4,705,950)
16.01.02 Accrued Interest on Short Term Loan

Interest Charged during the year 1,465,286 1,453,813
Payment made during the year (1,970,917) (877,244)
17.00 Liability for Contribution to WPPF

Opening Balance 6,115,435 4,381,155
Add: Provision for WPPF for the year (Note-17.01) 10,598,030 4,730,551
Less: Paid during the year (4,730,551) (2,996,271)
Total 11,982,914 6,115,435
17.01 Provision for WPPF for the year
5 % of profit before Tax 10,598,030 4,730,551
Total 10,598,030 4,730,551
18.00 Provision for Current Tax
Opening Balance 29,105,618 24,838,654
Add: Provision for tax during the year (Note-18.01) 29,817,062 4,266,964
Total 58,922,680 29,105,618
18.01 Provision for Tax during the year

Accounting Profit before Tax 211,960,605 94,611,028
Add: Other Inadmissible Allowances
Accounting Depreciation 24,632,842 24,163,026
Provision for WPPF 10,598,030 4,730,551
Other Income (6,935,771) -
Loss on disposal of Fixed Assets 1,662,857 -
Less: Items for Separate Consideration
IPO Expenses - (18,198,305)
Depreciation as per 3rd Schedule (125,459,940) (85,242,175)
Payment for WPPF (4,730,551) (2,996,271)
Loss as per Third Schedule (395,091) -
Total Taxable Income 111,332,981 17,067,854
Rate 25% 25%
Total Tax Expenses/Current Tax 27,833,245 4,266,964
Tax on Other Income 2,427,520 -
Adjustment for previous year:
For the Income year 2013 (2,127,626) -
For the Income year 2014 2,129,756 -
For the Income year 2015 1,799,178 -
For the Income year 2016(Jan.-June) (2,245,010) -
Total Tax Payable 29,817,062 4,266,964
Annual Report - 67
Amount in Taka
2018 - 2019 2017- 2018
19.00 Turnover
Sales Revenue from Sale of Finished Goods:
Gross Sales(Note: 19.01) 603,555,589 397,031,043
Less : VAT on Sales 1,589,092 982,769
Net Sales 601,966,497 396,048,274
19.01 Gross Sales Gross Sales VAT@15% Net Sales Net Sales
Vatable Sales 12,183,041 1,589,092 10,593,949 6,551,792
Non Vatable Sales 591,372,548 - 591,372,548 389,496,482
Total 603,555,589 1,589,092 601,966,497 396,048,274
20.00 Cost of Sales

Raw Materials Consumed (Note-20.01) 271,746,199 179,504,871
Manufacturing Overhead (Note-20.02) 50,766,448 46,793,042
322,512,647 226,297,913
Add: Opening Work in process 14,274,867 14,827,267
Less: Closing Work in process (13,546,890) (14,274,867)
Cost of Goods Manufactured 323,240,624 226,850,313
Add: Opening stock of finished Goods 19,265,698 17,249,988
Cost of Goods Available for Sale 342,506,322 244,100,301
Less: Closing stock of finished Goods (22,786,458) (19,265,698)
Less: Sample Distribution (1,573,288) (2,318,767)
Cost of Sales 318,146,576 222,515,836
20.01 Raw Materials Consumed

Opening Stock of Raw Materials 24,398,106 20,140,116
Add: Raw Materials Purchased (Note-20.01.01) 274,656,883 183,762,861
Raw Materials available for Consumption 299,054,989 203,902,977
Less: Closing Stock of Raw Materials (27,308,790) (24,398,106)
Raw Material Consumption 271,746,199 179,504,871
20.01.01 Raw Materials Purchase:

Local Purchase 264,352,802 171,981,135
Foreign Purchase 10,304,081 11,781,726
Total Purchase 274,656,883 183,762,861
20.02 Manufacturing Overhead

Wages and Salary 9,165,350 9,019,750
Festival Bonus 999,050 1,100,250
Overtime 1,429,950 1,692,965
Packaging Materials Consumed (Note - 20.02.01) 7,280,677 4,632,768
Spare Parts Consumed (Note - 20.02.02) 2,663,267 1,941,255
Repair & Maintenance 1,110,942 724,534
Electricity Bill 1,785,975 1,885,998
Disel & Fuel 848,748 814,102
Electric & Sanitary Goods 649,527 578,247
Fire Insurance Premium 101,049 101,049
Canteen Expenses 1,132,133 1,016,834
Laboratory Expenses 329,220 517,395
Cleaning & Washing 144,319 105,723
Internet bill 29,800 29,700
Mobile & Telephone bill 32,100 71,996
Uniform 186,710 281,476
Depreciation (Annexure-A) 22,877,631 22,279,000
Total 50,766,448 46,793,042
Annual Report - 68
Amount in Taka
2018 - 2019 2017- 2018
20.02.01 Packaging Materials Consumed
Opening Stock of Packaging Materials 5,372,560 4,212,567
Add: Purchase during the year 8,687,473 5,792,761
Less: Closing Stock of Packaging Materials (6,779,356) (5,372,560)
Packaging Materials Consumed 7,280,677 4,632,768
20.02.01 Spare Parts Consumed

Opening Stock of Spare Parts 370,452 467,452
Add: Purchase during the year 2,681,473 1,844,255
Less: Closing Stock of Spare Parts (388,658) (370,452)
Spare Parts Consumed 2,663,267 1,941,255
21.00 Administrative Expenses

Salary & Allowance 11,604,329 11,590,502
Director Remuneration (Note - 30.01) 1,200,000 1,080,000
Conveyance 185,655 278,083
Subscription, Gift & Donation 170,900 398,900
Festival Bonus 1,070,225 1,795,275
Office Rent including VAT 690,000 690,000
Board meeting attendance fees (Note - 30.01) 315,000 375,000
Cleaning & Sanitation 163,204 104,431
Credit Rating Fee 50,000 -
Electricity Bill 122,016 82,789
Entertainment 609,564 914,709
Garage Rent 12,500 26,000
Legal, License, Renewals & Professional fee 1,653,375 416,441
R & D Expenses 678,480 1,459,136
Miscellaneous Expense 1,559,767 1,640,938
Newspaper & Magazine 7,249 7,506
Postage, Stamps & Courier 98,018 142,375
Printing & Stationery 648,939 656,371
Office Maintenance 258,152 367,875
Training Allowance 88,410 79,800
Vehicle Repair & Maintenance 158,391 337,168
Fuel & Gas 614,579 440,457
Telephone & Mobile 137,044 167,997
Internet bill 92,250 57,300
Annual General Meeting Expenses 328,815 -
Audit fees including VAT 230,000 230,000
Depreciation (Annexure-A) 1,755,211 1,884,026
Total 24,502,073 25,223,079
22.00 Selling & Marketing Expenses

Salary & Allowance 17,092,270 17,085,620
Travelling & Conveyance 4,953,349 8,465,415
Festival Bonus 956,725 1,336,500
Advertisement 331,955 1,393,800
Marketing Promotion 4,038,750 8,174,280
Distribution Cost 7,344,599 7,477,874
Sample Distribution 1,573,288 2,318,767
Total 36,290,936 46,252,256
23.00 Financial Expenses

Bank Charges 332,626 175,358
Interest on Loan 5,408,565 5,574,522
Total 5,741,191 5,749,880
Annual Report - 69
Amount in Taka
2018 - 2019 2017- 2018
24.00 Other Income

Bank Interest 646,724 2,629,052
Gain on Foreign Currency Exchange (From USD to BDT) - 16,342
Sales of Wastage (Others) 1,572,255 -
Interest on FDR 4,716,792 388,962
Total 6,935,771 3,034,356
25.00 Other Loss

Total 1,662,857 -
Yearly Product
(Weighted Average)
30-Jun-2019 30-Jun-2018
26.00 Earnings Per Share (EPS)
Profit after tax 158,403,638 86,877,032
Weighted average number of ordinary shares outstanding 75,460,000 61,487,397
Earnings per share 2.10 1.41
This has been calculated in compliance with the requirements of IAS 33 Earnings per Share. EPS is the
earnings dividing by the weighted average number of ordinary shares outstanding at the end of the year.
26.01 Calculation of Weighted Average Number of Shares

Yearly Product
Share Outstanding Length in Daily
Particulars (Weighted Average)
Numbers Period Days Product
Weighted Average number of share
30-Jun-2019 30-Jun-2018
Shares at beginning 68,600,000 July-18 to June-19 365 25,039,000,000 68,600,000 48,600,000
Stock Dividend @ 10% 6,860,000 July-18 to June-19 365 2,503,900,000 6,860,000 6,860,000
New Shares issued 13 March-18 to
through IPO 20,000,000 30 June-18 110 2,200,000,000 - 6,027,397
Total 29,742,900,000 75,460,000 61,487,397
27.00 Net Asset Value (NAV) per Share 30-Jun-2019 30-Jun-2018
Total Asset 1,207,645,989 1,012,761,485

Less: Total outside Liability 189,011,547 138,810,681
Net Asset 1,018,634,442 873,950,804
Number of ordinary shares outstanding 75,460,000 68,600,000
Net Asset Value (NAV) per Share 13.50 12.74
28.00 Net Operating Cash Flows per Share(NOCFPS)

Net Cash Generated from Operating Activities 204,552,782 110,155,442
Weighted Average Number Shares Outstanding 75,460,000 61,487,397
Net Operating Cash Flows per Share(NOCFPS) 2.71 1.79
Annual Report - 70
29.00 Reconciliation of Net Profit with Cash Flows from Operating Activities: 30-Jun-2019 30-Jun-2018
Profit before Tax 211,960,605 94,611,028
Adjustment for:
Depreciation on property, plant and equipment 24,632,842 24,163,026
Financial Expenses 5,741,191 5,749,880
243,997,494 124,523,934
(Increase)/Decrease in Accounts Receivable (26,833,246) (5,438,793)
(Increase)/Decrease in Inventory (7,128,469) (6,784,293)
Increase/(Decrease) in Trade and Other Payables 58,241 (420,125)
(Increase)/Decrease in Advance, Deposit & Prepayments 147,273 307,754
Increase/(Decrease) in Liabilities for Expenses 364,500 253,834
Increase/(Decrease) in Liability for contribution to W.P.P.F 5,867,479 1,734,280
216,473,273 114,176,592
Less: Income Tax Paid (11,920,491) (4,021,149)
Net Cash Generated from Operating Activities 204,552,782 110,155,442
30.00 Related parties Transaction:

IAS-24 Related Party Disclosures, Parties are considered to be related if one of the party has the ability to
control the other party or exercise significant influence over the other party in making financial and operating
decision.
30.01 As per paragraph 17 of IAS 24 : Disclosure of key management personnel compensation.

a) Short-term employee benefits :
The amount of transaction for remuneration and board meeting fee during the period from 1 st July 2018 to 30 th
June 2019 are as follows:
Name Designation Remuneration Board meeting fee
A.K.M. Shafiqul Alam Chairman - 25,000
Wajhi Ahmed Managing Director 850,000 35,000
Mohammad Jawaid Yahya Ex -Managing Director 350,000 10,000
Mahmood Ali Nominee Director - 15,000
Kazi Rina Alam Director - 35,000
Faria Binta Alam Director - 35,000
Md. Tazul Islam Director - 30,000
Mohammad Towhidul Islam Nominee Director - 35,000
Asif Iqbal Chowdhury Nominee Director - 35,000
Mohammed Salim Independent Director - 30,000
Shekh Karimuzzaman Independent Director - 10,000
Shanzida Akhter Khanam Ex- Independent Director - 20,000
Total 1,200,000 315,000
b) Post employment benefits: Nil

c) Other long term benefits: Nil
d) Termination benefits: Nil
e) Share-based payment: Nil
Annual Report - 71
31.00 Disclosure as per Companies Act, 1994:
31.01 Disclosure as per requirement of Schedule XI, Part II, Note 5 of Para 3:
Employee position of the company as at June 30, 2019:
Officer & Staff Worker Total

Salary (Monthly)
Factory Head Office Employees
Below Tk. 3,000.00 - - - -

Above Tk. 3,000.00 48 189 46 283
for the year ended 30.06.2019 48 189 46 283
31.02 Attendance Status of Board Meeting of Directors

During the year Seven Board Meetings were held. The attendance status of the meetings are as follows:
Name of Directors Meeting Duration
Attended Position Total Fee
Held
A.K.M. Shafiqul Islam 7 5 15.10.18 to 30.06.19 Chairman 25,000
Wajhi Ahmed 7 7 01.07.18 to 30.06.19 Managing Director 35,000
Mohammad Jawaid Yahya 7 2 01.07.18 to 13.10.18 Ex-Managing Director 10,000
Mahmood Ali 7 3 01.07.18 to 15.10.18 Nominee Director 15,000
Kazi Rina Alam 7 7 01.07.18 to 30.06.19 Director 35,000
Faria Binta Alam 7 7 01.07.18 to 30.06.19 Director 35,000
Md. Tazul Islam 7 6 01.07.18 to 30.06.19 Director 30,000
Mohammad Towhidul Islam 7 7 01.07.18 to 30.06.19 Nominee Director
(Horipur Feed Ltd.) 35,000
Asif Iqbal Chowdhury 7 7 01.07.18 to 30.06.19 Nominee Director
(Farmers Hope Ltd.) 35,000
Mohammed Salim 7 6 01.07.18 to 30.06.19 Independent Director 30,000
Shekh Karimuzzaman 7 2 25.11.18 to 30.06.19 Independent Director 10,000
Shanzida Akhter Khanam 7 4 01.07.18 to 25.11.18 Ex-Independent Director 20,000
TOTAL 315,000
31.03 Disclosure as per requirement of Schedule XII, Part II, Para 4:

Payments to Managing Director and Directors by the Company during the year:
(a) Sl. No. Particulars 30-Jun-19
(a) Managerial remuneration paid or payable during the financial year to the directors,
including managing director, a managing agent or manager; 1,515,000
(b) Expenses reimbursed to the managing agent; Nil
(C) Commission or other remuneration payable separately to managing agent or his
associate; Nil
(d) Commission or other remuneration payable separately to managing agent or his
associate as selling or buying agent of other concerns in respect of contracts entered
into by such concerns with the company; Nil
(e) The money value of the contracts for the sale or purchase of goods and materials or
supply of services, entered into by the company with the managing agent or his
associate during the financial year; Nil
(f) Any other perquisites or benefits in cash or in kind; Nil
(g) Other allowances and commission including guarantee commission; Nil
(h) Pensions etc.- Nil
(i) Pensions Nil
(ii) Gratuities Nil
(iii) Payments from a provident funds, in excess of own subscription and interest thereon Nil
(iv) Compensation for loss of office Nil
(v) Consideration in connection with retirement from office. Nil
Annual Report - 72
31.04 Disclosure as per requirement of Schedule XI, Part II, Para 7:
Details of Production Capacity Utilization for the Year 2018-2019:
License Installed Actual Production Percentage of
Particulars Unit Capacity Per
Capacity per annum Capacity
Annum Utilization
Bolus Products Pcs N/A 15,120,000 2,654,540 18%
Powder Products Kg N/A 1,125,000 971,918 86%
Liquid Products Liter N/A 1,321,920 1,171,708 89%
31.05 Disclosure as per requirement of Schedule XI, Part II, Para 8 :
(a) Value of imports calculated on C.I.F basis by the company during the financial year 2018-2019 in respect
of Raw materials, Component and Spare parts and Capital Goods were as follows:
S.L Particulars Import

Amount in BDT
i Raw Materials 10,304,081
ii Packing Materials -
iii Components of Spare parts
iv Capital Goods 1,075,205
(b) The Company did not have any expenditure in foreign currency during the financial year on account of
Royalty, Know-how, Professional consultancy fees, Interest and other matters.
( c ) Value of both imported and Indigenous raw materials, Spare parts and components consumption thereon
were as follows:
Total Indigenous
Particulars Consumption Imported Value(in BDT) (%) (%)
Value(in BDT)
Raw Materials 271,746,199 19,188,229 7.06% 252,557,970 92.94%
Packing Materials 7,280,677 - 0% 7,280,677 100%
Spare Parts 2,663,267 - 0% 2,663,267 100%
Total 281,690,143 19,188,229 262,501,914
(d) No amount is remitted during the year in foreign currencies on account of dividend with a specific mention
of the number of non-residents shareholders, the number of shares held by them on which the dividends
were due and the year to which the dividends, related.
(e) Earnings in foreign exchange classified under the following heads as follows:
i) No export made during the year;
ii) No royalty , know -how, professional and consultation fees were received;
iii) No Interest and Dividend received;
iv) No Other income received.
Annual Report - 73
32.00 Contingent Liabilities
There is no sum for which the company is contingently liable as on 30.06.2019.
33.00 Events after the Reporting Period

Following events occurred since the balance sheet date:
(a) The board of directors recommended 2% cash and 10% stock dividend at the Board meeting held on
October 27, 2019 for the year ended June 30, 2019. This dividend is subject to final approval by the sharehold
ers at the forthcoming Annual General Meeting (AGM) of the company.
(b) Except for the fact stated above, no circumstances have arisen since the balance sheet date which would
require adjustment to, or disclosure in, the financial statements or notes thereto.
34.00 Significant Deviation

Our sales and net profit after tax have been increased during the year from July 01 2018 to 30 June 2019
compare to previous year from July 01 2017 to 30 June 2018. Hence earnings per share have been increased
compared to previous year. Due to increase of sales and proportionate lower increase of accounts receivable,
cash generated from operating activities has been increased during the current year compare to previous year,
resultant Net Operating Cash Flow Per Share has been increased during the current year compare to previous
year ended 30 June 2018.
Annual Report - 74
Advent Pharma Ltd.
Schedule of Property, Plant and Equipment
As at June 30, 2019
Annexure-A
Cost Depreciation Written down
Balance as on Addition Disposal Balance as on
Rate of Balance as Charged Adjustment value as on
on during during Balance as on
Particulars 01-July-2018 during the during the 30-June-2019
Dep. 30-June-2019
Year Year 01-July-2018 the year the year 30-June-2019
Land 3,783,816 - - 3,783,816 0% - - - - 3,783,816
Land Development 9,454,530 - - 9,454,530 2.5% 351,591 227,573 - 579,164 8,875,366
Factory Building 280,687,032 249,039,910 2,190,000 527,536,942 2.5% 14,458,360 7,119,800 276,376 21,301,784 506,235,158
Plant & Machinery 188,660,698 30,940,308 - 219,601,006 5% 23,490,200 8,710,635 - 32,200,835 187,400,171
Sub-Station 6,694,722 - 6,694,722 10% 1,770,728 492,399 - 2,263,127 4,431,595
Motor Vehicle 6,097,576 - 6,097,576 15% 2,080,197 602,607 - 2,682,804 3,414,772
Furniture & Fixture 6,445,900 179,980 - 6,625,880 10% 1,362,222 519,877 - 1,882,099 4,743,781
Solar Panel 2,004,740 - 2,004,740 10% 469,370 153,537 - 622,907 1,381,833
Generator 627,520 - 627,520 10% 268,984 35,854 - 304,838 322,682
Air Conditioner 3,763,120 44,000 - 3,807,120 5% 548,154 161,115 - 709,269 3,097,851
Office Equipment 5,544,268 519,175 - 6,063,443 10% 1,095,136 471,612 - 1,566,748 4,496,695
HVAC System 44,536,240 - 44,536,240 5% 4,165,994 2,018,512 - 6,184,506 38,351,734
Laboratory Equipment 51,322,810 - 51,322,810 5% 4,727,172 2,329,782 - 7,056,954 44,265,856
Product Development Equipment 20,725,781 - 20,725,781 5% 1,876,237 942,477 - 2,818,714 17,907,067
ETP 18,488,470 - 18,488,470 5% 1,656,259 841,611 - 2,497,870 15,990,600
Books & Journals 45,000 - - 45,000 15% 8,663 5,451 - 14,114 30,886
Total 648,882,223 280,723,373 2,190,000 927,415,596 58,329,267 24,632,842 276,376 82,685,733 844,729,863
Balance as at June 30, 2018 536,897,629 111,984,594 - 648,882,223 34,166,241 24,163,026 - 58,329,267 590,552,956
Allocation of Depreciation:
Administrative cost 1,755,211

Factory cost 22,877,631
Total 24,632,842
Annual Report - 75
Advent Pharma Ltd.
Schedule of Stock
As at June 30, 2019
Finished Goods Annexure-B
Name of Items 30-Jun-19 30-Jun-18

Unit
Non Vatable Goods Quantity Rate Amount Quantity Amount
Advit DB Premix-100 gm Sachet 646 18.70 12,080 1,307 24,441
Advit DB Premix-500 gm Sachet 1,587 80.12 127,150 1,089 87,251
Advit DB Premix-1 kg Bucket 1,501 150.55 225,976 1,575 237,116
Advit CP Suspention -500 ml Bottle 1,209 73.72 89,127 1,069 78,807
Advit CP Suspention -1 ltr. Bottle 1,241 127.35 158,041 1,135 144,542
Advit CP Suspention -5 ltr. Jar 1,171 536.10 627,773 1,320 707,652
Adzinc Syrup - 100 ml Bottle 2,716 20.05 54,456 2,057 41,243
Adzinc Syrup - 500 ml Bottle 1,450 73.58 106,691 2,534 186,452
Adzinc Syrup - 1 ltr. Bottle 2,477 133.80 331,423 2,052 274,558
Adzinc Syrup - 3 ltr. Bottle 1,233 375.10 462,498 1,043 391,229
Adlyte Powder -100 gm Sachet 1,034 13.40 13,856 1,357 18,184
Adlyte Powder -500 gm Sachet 1,856 53.60 99,482 1,336 71,610
Adlyte Powder -1 kg Sachet 1,037 80.40 83,375 1,211 97,364
Advit( B+C )-100 gm Sachet 1,302 32.22 41,950 1,567 50,489
Advit( B+C )-500 gm Sachet 1,056 134.12 141,631 455 61,025
Advit WS-100 gm Sachet 650 153.85 100,003 742 114,157
Advit GC-500 gm Sachet 2,657 56.90 151,183 1,002 57,014
Advit GC-1 kg Sachet 1,895 107.12 202,992 1,016 108,834
Advit C-100 gm Sachet 1,745 110.65 193,084 1,037 114,744
Advit C-500 gm Sachet 1,847 390 720,330 - -
Advit CP Plus Bolus Bolus 3,754 46.90 176,063 1,470 68,943
Advit D Plus -100 ml Bottle 1,735 46.73 81,077 1,635 76,404
Advit AD3E-100 ml Bottle 1,544 87.19 134,621 1,943 169,410
Advit AD3E-500 ml Bottle 1,572 395.50 621,726 2,236 884,338
Adzoril Solution-100 ml Bottle - 247.75 - 1,929 477,910
Adbovi Powder-125 gm Sachet 1,851 120.55 223,138 1,299 156,594
Adcal P Powder-250 gm Sachet - 87.10 - 1,343 116,975
Adcal P Powder-500 gm Sachet 1,098 167.55 183,970 1,476 247,304
Advit 3 Powder-100 gm Sachet - 50.35 - 992 49,947
Adzyme Powder-100 gm Sachet 1,924 93.72 180,317 1,889 177,037
Cough of Oral Solution-100 ml Bottle 3,872 63.62 246,337 4,904 311,992
Cough of Oral Solution-500 ml Bottle 2,946 308.15 907,810 2,111 650,505
Cough of Oral Solution-1 Ltr. Bottle 1,605 589.55 946,228 2,812 1,657,815
Advit E-Sel-100 Ml Bottle 1,950 56.80 110,760 1,637 92,982
Feron Vet-500 Ml Bottle 1,590 67.10 106,689 1,943 130,414
Feron Vet-1 Ltr. Bottle 2,439 134 327,314 - -
ABC -100 Ml Bottle 3,060 60.35 184,671 3,137 189,318
ABC -500 Ml Bottle 2,997 247.92 743,016 1,988 492,865
ABC -1 Ltr. Bottle 1,645 465.67 766,027 2,732 1,272,210
Lever on-100 Ml Bottle 2,186 46.86 102,436 1,983 92,923
Annual Report - 76
Lever on-500 Ml Bottle 1,055 207.65 219,071 1,572 326,426
Lever on-1 Ltr. Bottle 1,462 391.90 572,958 2,272 890,397
Nephrosol-100 ml Bottle 2,573 190 488,870
Nephrosol-500 ml Bottle 1,865 900 1,678,500
Egg Bost-100 gm Sachet 2,448 130 318,240
Egg Bost-500 gm Container 1,275 625 796,875
Power Fat-1 kg Sachet 8,605 184.25 1,585,470 607 111,840
Oramin Solution-100 ml Bottle 3,557 110 391,270
Oramin Solution-500 ml Bottle 2,282 510 1,163,820
Oxi D Bolus Container 5,617 165 926,805
Advit B Complex-100 ml Bottle 2,650 55 145,750
Advit B Complex-500 ml Bottle 1,752 260 455,520
Adzinc B-100 ml Bottle 2,420 52 125,840
Adzinc B-500 ml Bottle 900 245 220,500
SubTotal 19,074,790 11,511,261
Vatable Goods Unit Quantity Rate Amount Quantity Amoun

Advomica Powder-20 gm Sachet 7,270 6.20 45,074 15,432 95,678
Aadcipcin Solution-100 ml Bottle 1,268 117.92 149,523 2,892 341,025
Aadcipcin Solution-500 ml Bottle 1,937 522.62 1,012,315 3,452 1,804,084
Adlinsin Powder-500 gm Container - 730.23 - 1,317 961,713
Adlinsin Powder-100 gm Sachet - 169.09 - 4,703 795,230
Adrizole Bolus Box 1,017 82.05 83,445 1,321 108,388
Adtetra Bolus Box - 30.81 - 1,132 34,877
Apetonic Bolus Box 1,852 68.81 127,437 3,997 275,034
Adcet Bolus Box 6,506 22.40 145,734 925 20,720
Adsulph Bolus Box - 208.42 - 1,319 274,906
Adsulph S Bolus Box - 208.41 - 1,107 230,710
Adprozine Bolus Box 6,862 99.57 683,249 2,090 139,428
Adtetra Powder-100 gm Sachet 886 43.23 38,302 2,102 90,869
Adprolim Plus Powder-100 gm Sachet 1,054 136.44 143,808 1,013 138,214
Adlosin Powder -500 gm Container - 405.30 - 1,413 572,689
Colis Vet-100 gm Sachet - 85.80 - 1,881 161,390
Colis Vet-500 gm Sachet - 381.60 - 1,333 508,673
Neocin Vet-100 gm Sachet - 169.80 - 1,025 174,045
Neocin Plus Vet-100 gm Sachet - 219.90 - 2,227 489,717
Microfix Powder-100 gm Sachet - 212.02 - 2,533 537,047
Neo Super Plus Vet-100 gm Sachet - 285.44 -
Adzyl Bolus Box 1,616 72.61 117,338
Keto Pain Bolus(5x4) Box 2,803 130.43 365,595
Keto Pain Bolus(10x4) Box 913 302.17 275,881
Adcipcin Bolus(10x2) Box 973 260.87 253,827
TCL Vet(5x4) Box 894 302.17 270,140
SubTotal 3,711,668 7,754,437
Grand Total 22,786,458 19,265,698
Annual Report - 77
Raw Materials
30-Jun-19 30-Jun-18
Name of Items Unit
Quantity Rate Amount Quantity Amount
Acetic Acid Glocial Kg 20.00 560 11,200 22.50 12,600
Aerosil-200, BP Kg 235.02 700 164,514 40.00 29,996
Albendazol Kg 530.05 1,500 795,075 434.00 651,053
Amonium Bi Carbonate Kg 432.00 82 35,424 308.80 9,882
Amprolium HCL Kg 129.35 3,300 426,855 190.80 470,646
Ascorbic Acid (Vitamin C) Kg 752.80 760 572,128 1,689.60 1,284,096
Avicel-PH 101, BP Kg 1,723.40 268 461,871 2,493.70 668,960
Avicel-PH 102, BP Kg 64.00 330 21,120 53.28 17,582
Avicel RC 591, BP Kg 205.00 530 108,650 185.07 98,087
Benzyl Alcohol, BP Kg 313.64 400 125,456 329.60 102,177
Benzyl Benzoate Kg 10.62 475 5,045 3.68 1,746
Biotin 2 % Kg 8.67 2,150 18,641 5.29 11,373
Butylated Hydroxytluene(Powder) Kg 10.19 1,875 19,106 1.15 2,153
Butylated Hydroxytluene(Liquid) Kg 8.31 7,000 58,195 1.31 2,463
Calcium Chloride, BP Kg - 125 - 12.20 1,525
Calcium Chloride Dihydrate Kg 763.00 50 38,150 527.88 23,755
Calcium D Panthothenate Kg 422 3,300 1,393,161 132.00 976,802
Calcium Lactate Pantahydrate, BP Kg 225.00 240 54,000 261.66 62,798
Calcium Propionate Kg 36.74 350 12,859 539.00 118,580
Calcium Premix Kg 609.41 20 12,188 437.59 6,564
Cetrimide Kg 25.00 1,350 33,750 26.72 36,071
Choline Bitartrate, BP Kg 2.93 3,800 11,134 14.06 53,420
Cholistin Sulphate Kg 137 1,700 232,900 161.50 205,195
Chocolate Brown Colour Kg 1.66 1,600 2,656 1.66 2,656
Cholin Choride Kg 26.99 105 2,834 47.63 5,001
Chlohexidine Gluconate Liquide Kg 5.50 1,350 7,425 5.50 7,425
Ciprofloxacin Hydrochloride, USP Kg 114.15 2,625 299,644 44.92 116,784
Citric Acid, Monohydrate, BP Kg 165.69 120 19,883 186.51 22,381
Citric Acid Anhydrous Kg 142.03 110 15,623 199.62 23,954
CMC Sodium, BP Kg 58.11 500 29,055 118.56 71,139
Calcium Gloconate Kg 18.60 1,850 34,410
Cobalt Gluconate Kg 10.78 1,850 19,943 19.91 36,835
Cobalt Sulphate, BP Kg 50.31 2,700 135,837 82.01 246,037
Color FD & C Red # 40, LAKE Kg 1.00 3,500 3,500 1.10 3,850
Color FD & C Allora Red # 40, Ph, Grade Kg 21.99 3,500 76,965 1.28 4,478
Color Egg Yellow Kg 1.39 1,200 1,663 1.39 1,663
Color Erythrosin Kg 14.99 765 11,467 1.06 9,023
Copper Sulphate Kg 41.60 765 31,826 41.60 31,826
Clorsulon USP Kg - 12,372 - 50.00 618,608
Clove Oil Kg 1.49 200 298 2.19 3,950
Cyanocobalamin, Vitamin B12(100%) BP Kg 0.015 500,000 7,500 0.02 9,350
Cyanocobalamin, Vitamin B12(1%) BP Kg 2.23 10,500 23,415 8.10 34,827
Annual Report - 78
30-Jun-19 30-Jun-18
Name of Items Unit
Dark Chocolate Colour Kg 1.00 1,600 1,600 1.10 1,760
Dextrose Anhydrous, BP Kg 4,075.69 87 354,585 2,385.88 226,658
Di Calcium Phosphate Dihydrate, BP Kg 512.00 140 71,680 209.90 12,594
DCP Anhydrous Kg 1,234.20 140 172,788 220.00 30,800
Doxacycline Hyclate Kg - 7,240 - 81.69 464,020
Dried Ferrous Sulphate, BP Kg 284.86 85 24,213 200.79 17,067
Disodium Hydrogen Phosphate Anhydrous Kg 382.02 175 66,854 158.61 28,549
DL-Metheonine Kg 548.74 280 153,647
Essence of Banana, PH, Grade Kg 36.08 800 28,864 34.23 29,098
Essence of Sweet Orange Flavour, Ph Grade Kg 26.00 800 20,800 25.17 22,650
Essence of Pineaple, Ph Grade Kg 32.05 800 25,640 28.01 23,805
Essence of Strawberry Flavour Kg 17.71 800 14,168 32.24 27,405
Essence of Rasberry Flavour Kg 23.20 800 18,560 21.19 16,954
Essence of Lemon Sparkle Kg 0.09 1,600 144 1.09 1,750
Erythromycin Thiocanate Kg - 6,500 - 36.54 123,175
Eucalyptus Oil Kg 0.63 1,800 1,134 1.24 2,488
EDTA Disodium Solt Kg 0.42 400 168
Egg Yellow Colour Kg 2.66 1,200 3,192
FD & C Yellow # 10 Kg 2.60 3,500 9,100 1.57 5,506
Ferrous Sulphate Hepthahydrate Kg 36.44 30 1,093 16.94 508
Folic Acid Kg 66.31 7,000 464,170 7.23 68,673
Genger Powder Kg 19.60 400 7,840 51.37 14,897
Gention Powder Kg 27.69 400 11,076 46.78 14,970
Glycerin, BP Kg 495.34 98 48,543 233.71 35,056
Haltox (Antioxident) Kg 37.60 165 6,204 82.95 13,686
Inositol Kg 10.99 1,300 14,287 18.65 24,239
Iso Propyle Alcohol Kg 34.00 170 5,780 37.40 6,358
Ivermectin Kg - 21,768.27 - 10.00 217,683
Justica Adha Ltr. 83.75 1,062 88,943
Ketoprofen Kg 59.78 7,800 466,284 49.87 401,896
Lactic Acid, BP(80%) Kg 362.00 205 74,210 173.30 36,392
Lactose Mono Kg 108.42 200 21,684 182.01 43,683
Lequid Paraffin Kg 132.66 85.00 11,276 146.15 12,400
Lemon Sweet Flavour Kg 1.00 1,200 1,200 1.10 1,320
Lemon Yellow Colour,Ph. Grade Kg 2.94 1,200 3,528 5.49 6,587
Levamisole Hydrochloride Kg 131.52 3,044.35 400,393 100 304,435
Levender Oil Kg 0.24 2,800 672 1.26 3,539
L-Lysine Kg 394 133.18 52,530 19,064 2,538,944
Ludipress Kg 25.68 1,700 43,656 25.68 43,656
Magnesium Oxide, Light Kg 155.15 325 50,424 399.76 103,937
Magnesium Stearate, BP Kg 190.97 165 31,510 132.27 21,824
Mazie Strach Kg 759.06 85 64,520 180.00 15,300
Manganese Sulphate Kg 465.76 130 60,549 385.36 50,096
Magnesium Sulphate Kg 484.14 25 12,104 26.52 796
Annual Report - 79
30-Jun-19 30-Jun-18
Name of Items Unit
Manitol Kg 10.95 420 4,599 11.05 4,639
Methyl Paraben(Methyl Hydroxy, Benzoate) Kg 31.58 650 20,527 22.44 14,586
Methyl Paraben(Sodium) Kg 16.55 700 11,585 44.51 31,160
Metronedazole Kg 192.50 1,200 231,000 145.17 171,301
Mint Flavour Kg 21.00 1,000 21,000 11.88 11,880
MP Zyme Kg 455.00 250 113,750 112.20 28,050
Niacinamide Kg 154.99 680 105,393 58.72 82,205
Neomycin Sulphate Kg 562.41 1,700 956,097 166.93 216,715
Nux Vomica Powder Kg 232.10 300 69,630 32.62 4,566
Nytric Acid Liquide Kg 390.00 70 27,300 154.78 10,834
Oxytetracycline HCL Kg 726.62 877.43 637,558 637.80 559,625
Polyethelene Glycol(PEG 6000) Kg 315.40 350 110,390 42.79 14,977
Polyethelene Glycol(PEG 400) Kg 8.90 420 3,738 5.03 2,114
Paracitamol, BP Kg 688.42 420 289,136 51.86 21,781
Polysorbate (Tween 80) Kg 156.00 260 40,560 132.45 34,437
Polyoxyl Castrol Oil Kg 176.69 340 60,075 80.19 27,265
Potacium Chloride, BP Kg 465.10 50 23,255 178.89 8,945
Potassium Iodide, GR Grade Kg 2.64 1,000 2,640 1.07 1,071
Povidone-K 30, BP Kg 1,490.32 444.15 661,926 720.83 320,157
Promethazine HCL Kg 91.53 5,800 530,874 22.20 110,617
Phosphoric Acid 85% Ltr. 12.64 2,800 35,392
Propilene Glycol(P.G) Kg 877.00 185 162,245 63.55 11,756
Propyl Paraben(Propyl Hydroxy Benzoate) Kg 16.51 900 14,859 6.07 5,459
Propyl Paraben Sodium Kg 12.53 950 11,904 9.79 9,301
Purified Talcum, BP Kg 57.20 80 4,576 88.98 7,118
Pyrodoxine Hydrochloride, (Vit. B6) Kg 124.93 6,500 812,045 35.46 230,487
Rasbery Red Colour Kg 12.03 1,800 21,654 8.65 15,577
Rivoflavin, (Vit, B2) Kg 308.40 5,500 1,696,200 29.99 164,923
Rivoflavin, Sodium 5 Phosphate(Vit, B2) Kg 35.16 10,000 351,600 21.23 201,675
Sodium Benzoate Kg 56.77 150 8,516 48.74 7,798
Sodium Bicarbonate, BP Kg 913.05 42 38,348 138.53 7,203
Sodium Chloride, BP Kg 712.16 32 22,789 127.77 4,089
Sodium Cytrate Dihydrate, BP Kg 120.00 110 13,200 91.75 10,092
Sodium Floride Kg 1.40 4,000 5,600 0.54 2,165
Sodium Hydroxied Crystal, BP Kg 1,036.00 110 113,960 24.43 2,443
Sodium Molybdate Dihydrate, GR Grade Kg 1.67 14,000 23,380 0.83 11,550
Sodium Saccharin, BP Kg 51.25 690 35,363 11.48 8,840
Sodium Selinate Anhydrous Kg 11.47 12,000 137,640 1.13 13,529
Sodium Strach Gyclolate Kg 947.62 323.35 306,413 564.30 182,466
Sorbitor 70% Kg 583.00 84 48,972 686.44 58,347
Steptomycine Sulphate Kg - 3,400 - 13.89 61,124
Strawberry Flavour(Powder) Kg 4.70 1,000 4,700 12.32 9,856
Sucrose, Food Grade Kg 2,500 53 132,500 281.58 14,924
Sulphadiazine Kg 150.00 1,677.93 251,690 995.05 1,669,623
Annual Report - 80
30-Jun-19 30-Jun-18
Name of Items Unit
Sulphadiazine Sodium Kg 54.65 1,859.61 101,628 187.43 348,545
Sulphadimidine Kg 106.24 893.77 94,954 714.57 638,662
Sulphapyridine Kg 211.63 1,681.12 355,775 755.98 1,270,885
Sulpha Qunioxaline Sodium Kg 65.63 1,551.45 101,822 358.72 556,538
TCP Kg 1,425.55 67.27 95,897 3,307.84 222,518
Thaym Oil Kg 10.87 2,200 23,914 1.22 2,674
Thaymol Kg 10.76 1,200 12,912 1.26 1,511
Threonine Kg 102.49 170 17,423 44.00 7,480
Thiamine HCL, BP(Vit.B1) Kg 129.74 6,500 843,310 26.84 193,232
Thiamine Mononytrate, BP(Vit.B1) Kg 120.55 6,000 723,300 24.70 205,042
Toltrazoril Kg - 34,000 - 37.05 1,259,700
Triclabendazole Kg 425.20 4,335.06 1,843,268 247.50 1,072,927
Trimethoprime Powder Kg 121.04 2,311.95 279,838 46.04 106,442
Turtaric Acid Kg 176.34 350 61,717 52.34 18,319
Tylosin Tartrate, BP Kg 498.33 4,800 2,391,984 328.41 702,296
Utrosol Ltr. 9,803 134.98 1,323,244 8,957 1,209,048
Vegetable Fat Kg 4,726 94 444,244 1,000 100,000
Vitamin A Acetate, USP (5 lac i.u./gm) Kg 124.91 6,800 849,388 35.13 122,965
Vitamin A Palmitate Oil, USP (17 lac i.u./gm) Kg 16.99 19,000 322,810 7.56 139,805
Vitamin D3(5 lac) Kg 117.13 4,000 468,520 23.87 143,200
Vitamin D3(Oily Form,5 lac) Kg 4.91 14,200 69,722 15.80 252,800
Vitamin D2 (oily form), BP, 1.6 MIU /gm Kg - 6,500 - 12.33 80,113
Vitamin E Liquid Kg 22.87 2,950 67,467 14.58 43,725
Vitamin E 50% Kg 26.12 900 23,508 30.76 76,907
Vitamin K3 Kg 21.25 1,400 29,750 4.50 5,963
Vanila Flavour Kg 11.20 800 8,960 8.68 6,948
Zinc Sulphate Monohydrate, BP Kg 547.14 550 300,927 217.25 108,626
Dry Lemon Flavour Kg 11.00 1,000 11,000 0.50 500
Dry Rasberry Flavour Kg 10.95 1,000 10,950 0.35 350
Dry Orange Flavour Kg 11.00 1,000 11,000 0.65 650
Grand Total 27,308,790 24,398,106
Annual Report - 81
Packing Material
Name of Items 30-Jun-19 30-Jun-18

Unit
Master Carton: Quantity Rate Amount Quantity Amount
Advit DB Premix-100 gm Sachet 646 18.70 12,080 1,307 24,441
Master Carton-A Pcs 3,167 27.00 85,509 1,373 39,817
Master Carton-B Pcs 2,245 20.00 44,900 1,023 19,437
Master Carton-C Pcs 3,258 21.50 70,047 1,239 28,497
Master Carton-D Pcs 3,509 21.00 73,689 862 18,102
Master Carton-E Pcs 2,318 15.50 35,929 1,125 21,375
Master Carton-F Pcs 3,364 29.00 97,556 1,240 35,960
Master Carton-G Pcs 2,072 20.00 41,440 1,016 20,320
Master Carton-H Pcs 1,914 27.50 52,635 428 11,128
Master Carton-I Pcs 2,928 17.50 51,240 1,992 35,856
Master Carton-J Pcs 2,021 22.00 44,462 362 7,964
Master Carton-K Pcs 1,025 33.00 33,825 1,922 67,270
Master Carton-L Pcs 2,020 21.00 42,420 1,589 38,931
Master Carton-M Pcs 1,630 24.00 39,120 1,318 28,996
Master Carton-N Pcs 950 32.50 30,875 1,200 40,800
Master Carton-O Pcs 1,958 22.50 44,055 200 4,400
Master Carton-P Pcs 1,534 14.50 22,243 - -
Sub Total 809,945 418,853
Sticker Label: Quantity Rate Amount Quantity Amount

Adzinc Syrup-100 ml Pcs 6,209 0.75 4,657 13,922 10,442
Adzinc Syrup-500 ml Pcs 4,436 1.90 8,428 6,724 12,103
Adzinc Syrup-1 Ltr. Pcs 8,610 2.20 18,942 3,302 6,934
Adzinc Syrup-3 Ltr. Pcs 2,000 4.75 9,500 2,567 10,910
Adlinsin Powder-500 gm Pcs - 2.20 - 1,120 3,248
Advit CP Suspension-500 ml Pcs 6,410 1.30 8,333 3,529 4,588
Advit CP Suspension-1 Ltr. Pcs 8,004 1.50 12,006 11,714 23,428
Advit CP Suspension-5 Ltr. Pcs 1,535 6.80 10,438 2,380 15,351
Adcipcip Oral Solution-100 ml Pcs 1,589 0.75 1,192 7,224 5,418
Advit D Plus-100 ml Pcs 8,525 1.00 8,525 10,752 12,365
Advomica Powder-20 gm Sachet Pcs 2,125 1.00 2,125 2,959 2,959
Advit DB Powder-500 gm Pcs 1,900 1.90 3,610 1,253 2,381
Advit DB Powder-1 kg Pcs 1,395 2.80 3,906 1,730 4,844
Adcipcip Solution-500 ml Pcs 5,076 3.10 15,736 1,488 2,232
Adtetra Powder-100 gm Pcs 2,747 3.30 9,065 1,991 4,978
AD3E Solution -100 ml Pcs 1,126 0.70 788 1,568 1,176
AD3E Solution -500 ml Pcs 5,000 1.80 9,000 6,962 12,532
Adzuril Syrup-100 ml Pcs - 11.10 - 470 1,128
Adzyme Powder-100 gm Pcs 4,589 4.10 18,815 1,364 5,592
Advit DB Powder-Small Label Pcs 9,171 0.80 7,337 3,893 3,426
Round Label for DB-1 kg Pcs 1,910 1.00 1,910 6,564 6,564
Sticker Label-250 gm Pcs 17,716 0.30 5,315 24,668 7,400
Annual Report - 82
Sticker Label: Quantity Rate Amount Quantity Amount
Advit E-Sel- 100 ml Pcs 4,975 0.70 3,483 1,402 981
Cough of Oral Solution-100 ml Pcs 7,092 0.78 5,532 11,826 10,643
Cough of Oral Solution-500 ml Pcs 5,281 2.40 12,674 8,096 19,430
Cough of Oral Solution-1 Ltr. Pcs 1,023 2.75 2,813 2,506 6,892
Colis Vet 100 gm Pcs - 3.20 - 2,339 7,485
Colis Vet 500 gm Pcs - 2.40 - 1,305 3,132
Microfix Vet 100 gm Pcs - 3.30 - 1,258 4,151
Neocin Vet 100 gm Pcs - 2.80 - 4,228 11,838
Neocin Plus Vet 100 gm Pcs - 3.30 - 1,488 4,910
ABC 1 Ltr. Pcs 4,982 2.75 13,701 2,506 6,892
ABC 500 ml Pcs 7,571 3.40 25,741 7,224 17,338
ABC 100 ml Pcs 6,340 0.78 4,945 14,481 10,861
Advit C-500 gm Pcs 1,800 3.40 6,120 - -
Liver on 1 Ltr. Pcs 3,051 2.75 8,390 1,564 4,301
Liver on 500 ml Pcs 2,942 3.40 10,003 2,228 5,347
Liver on 100 ml Pcs 4,376 0.78 3,413 6,704 5,028
Feron Vet 500 ml Pcs 4,420 3.40 15,028 6,163 14,791
Feron Vet 1 Ltr. Pcs 4,108 4.00 16,432 204 592
Neprosol 500 ml Pcs 2,984 1.80 5,371 5,172 9,310
Neprosol 100 ml Pcs 2,840 0.75 2,130 8,883 6,662
Power Fat 1 kg Pcs 6,284 6.00 37,704 3,984 23,904
Adcal P-500 gm Pcs 2,946 3.65 10,753 766 2,681
Egg Bost-100 gm Pcs 2,633 3.45 9,084 - -
Egg Bost-500 gm Pcs 3,195 3.65 11,662 - -
Oxi D Bolus Pcs 4,350 1.10 4,785 - -
Oramin 500 Ml Pcs 3,510 2.50 8,775 - -
Oramin 100 Ml Pcs 2,936 0.78 2,290 - -
Advit B Complex-100 Ml Pcs 2,993 0.78 2,335 - -
Advit B Complex-500 Ml Pcs 2,392 3.40 8,133 - -
Adzinc B-100 Ml Pcs 2,954 0.78 2,304 - -
Adzinc B-100 Ml Pcs 2,880 1.90 5,472 - -
Utrosol-500 Ml Pcs 10,000 1.90 19,000 - -
Sub Total 417,701 337,168
Annual Report - 83
Sachet: Unit Quantity Rate Amount Quantity Amount
Adlyte Powder-100 gm Pcs 31,192 3.00 93,576 43,432 130,296
Adlyte Powder-500 gm Pcs 31,118 5.00 155,590 44,827 224,135
Adlyte Powder-1 kg Pcs 10,693 6.65 71,108 18,403 122,380
Advit GC Powder-500 gm Pcs 14,611 5.00 73,055 34,606 173,030
Advit GC Powder-1 kg Pcs 20,398 6.65 135,647 28,663 190,609
Advit WS Powder-100 gm Pcs 51,493 3.00 154,479 35,454 106,362
Advit C Powder-100 gm Pcs 37,507 3.00 112,521 50,058 150,174
Advit DB powder-100 gm Pcs 31,284 3.00 93,852 40,094 120,282
Advit (B+C) Powder-100 gm Pcs 50,808 3.00 152,424 71,448 214,344
Advit (B+C) Powder-500 gm Pcs 31,274 5.00 156,370 43,546 217,730
Unprinted Sachet-100 gm(Milky White) Pcs 13,133 2.75 36,116 3,250 10,498
Advomica Powder-20 gm Pcs 20,318 1.10 22,350 111,085 115,528
Un Printed Sachet-Advomica 20 gm Pcs - 1.22 - 1,971 2,385
Adbovi Powder-125 gm Pcs 19,449 3.35 65,154 46,756 156,165
Adcal P Powder-500 gm Pcs 14,866 5.15 76,560 31,805 160,933
Advit 3 Powder Pcs 19,984 3.30 65,947 34,213 113,587
Adlinsin-100 gm Pcs - 2.90 - 29,422 85,030
Adprolim Plus-100 gm Pcs 10,076 2.90 29,220 32,221 92,796
Printed Alu Sachet-500 gm Pcs 19,767 4.60 90,928 18,751 86,255
Printed Alu Sachet-1 kg Pcs 11,006 6.00 66,036 2,263 13,239
Unprinted Sachet for DB -500 gm Pcs 9,728 1.90 18,483 5,345 9,728
Unprinted Sachet for DB -1 kg Pcs - 2.12 - 5,604 11,880
Sub Total 1,669,416 2,507,366
Insert: Unit Quantity Rate Amount Quantity Amount

Adcet Bolus Pcs 18,862 0.20 3,772 18,876 3,775
Apetonic Bolus Pcs 18,161 0.20 3,632 6,975 1,395
Adcipcin Oral Solution -100 ml Pcs 9,905 0.25 2,476 523 63
Adtetra Bolus Pcs 9,274 0.20 1,855 5,951 1,190
Adrizole Bolus Pcs 12,333 0.25 3,083 12,958 3,240
Adzinc Bolus Pcs 6,482 0.12 778 9,026 1,083
Advit CP Plus Bolus Pcs 19,763 0.20 3,953 12,973 2,595
Adsulph Bolus Pcs - 0.20 - 16,645 3,329
Adsulph S Bolus Pcs - 0.20 - 16,848 3,370
Adzuril-100 ml Pcs - 0.20 - 7,271 1,454
Adlincin 100 gm Sachet Insert Pcs - 0.20 - 13,833 2,767
Adzyl Bolus Pcs 10,683 0.20 2,137 9,730 1,946
Adprozine Bolus Pcs 13,070 0.30 3,921 1,630 652
Keto Pain Bolus(5x4) Pcs 10,395 0.30 3,119 - -
Adcipcin Bolus Pcs 11,272 0.30 3,382 - -
TCL Bolus Pcs 10,251 0.30 3,075 - -
Sub Total 35,183 26,859
Annual Report - 84
Inner Carton /Box: Unit Quantity Rate Amount Quantity Amount
Adcet Bolus Pcs 8,365 2.10 17,567 13,234 27,791
Apetonic Bolus Pcs 5,543 4.55 25,221 12,739 57,962
Adrizole Bolus Pcs 5,566 2.55 14,193 1,243 4,288
Advit CP Plus Bolus Pcs 5,495 4.50 24,728 15,412 69,354
Advit D Plus Oral Solution-100 ml Pcs 9,708 2.30 22,328 7,048 16,210
Advomica Powder-20 gm Pcs 6,774 4.00 27,096 11,484 45,936
Adzinc Bolus Pcs 1,465 1.70 2,491 2,040 3,468
Adtetra Bolus Pcs 8,092 2.50 20,230 11,268 28,170
Adcipcin Oral Solution-100 ml Pcs 5,286 3.00 15,858 6,511 19,533
Adcipcin Oral Solution-500 ml Pcs 4,063 8.00 32,504 - -
Adsulph Bolus Pcs - 2.55 - 2,198 5,605
Adsulph S Bolus Pcs - 2.55 - 2,735 6,974
Adzuril Syrup- 100 ml Pcs - 5.00 - 145 725
Adlinsin -100 gm Pcs - 12.00 - 2,156 25,872
Adprolim Plus-100 gm Pcs 6,252 12.00 75,024 3,261 39,132
Cough Off-100 ml Pcs 6,300 2.60 16,380 5,692 14,799
Adzyl Bolus Pcs 6,867 2.80 19,228 12,954 36,271
Neprosol 100 ml Pcs 4,681 2.40 11,234 6,350 15,240
Adprozine Bolus Pcs 8,531 3.70 31,565 1,604 5,935
Adcipcin Bolus(10x2) Pcs 7,270 2.80 20,356 - -
TCL Bolus(5x4) Pcs 8,172 2.60 21,247 - -
Sub Total 442,899 423,265
Annual Report - 85
Bottle & Accessories: Unit Quantity Rate Amount Quantity Amount
HDPE Bottle with Handle & Cap 1000 ml Pcs 4,938 17.00 83,946 3,250 71,500
HDPE Bottle with Handle & Cap 500 ml Pcs 6,679 12.50 83,488 881 11,145
HDPE Bottle with Handle & Cap -3 Ltr. Pcs 3,080 37.00 113,960 1,315 43,395
HDPE Bottle Round with Cap 500 ml Pcs 5,730 16.10 92,253 1,465 23,587
100 ml pet bottle(Amber) Pcs 16,632 4.17 69,355 12,450 49,427
100 ml pet bottle(Milky White) Pcs 18,606 3.45 64,191 11,250 44,663
100 ml pet bottle(Transperant) Pcs 11,259 3.45 38,844 10,240 35,328
500 ml pet bottle(Transparent) Pcs 3,492 12.00 41,904 1,992 23,904
1000 ml pet bottle(Transparent) Pcs 5,518 21.00 115,878 892 19,481
500 ml pet bottle(Transparent) with red cap Pcs 9,015 12.00 108,180 6,505 89,769
Plastic Bucket-1 kg(White) Pcs 3,621 25.50 92,336 1,613 41,132
Plastic Container-500 gm Pcs 2,746 13.00 35,698 3,184 41,392
Plastic Container-500 gm(Round) Pcs 5,870 14.00 82,180 1,424 18,512
Plastic Container-500 gm(Square) Pcs 5,160 23.00 118,680 2,288 52,624
Plastic Container-100 gm(Square) Pcs 2,463 6.50 16,010 - -
Blue Jar-5 Ltr. Pcs - 120.75 - 443 53,492
5 Ltr. Jar(New) Pcs 1,132 70.00 79,240 454 30,418
5 Ltr. Jar(Milky White) Pcs - 109.00 - 16 1,744
Measuring Cup 15 ml Pcs 21,630 0.36 7,787 3,574 1,287
EP Liner for 500 ml Container Pcs 1,980 0.60 1,188 3,094 1,856
HDPE Bottle with purple ring 500 ml Pcs 16,288 18.50 301,328 10,322 190,957
PP Cap 28 mm Pcs 36,553 1.25 45,691 - -
Sub Total 1,981,934 976,718
PVC Flim: Unit Quantity Rate Amount Quantity Amount

PVC Sheet (180 mm x 350 mic)-Glass Clear Kg 440.51 155.00 68,279 377 60,264
PVC Sheet (204 mm x 350 mic)-Glass Clear Kg 910.00 155.00 141,050 356 69,323
PVC Sheet (204 mm x 350 mic)-Milky White Kg 1,528.20 195.00 297,999 180 35,139
Sub Total 507,328 164,726
Aluminium Bottom Foil Unit Quantity Rate Amount Quantity Amount

Alu Alu Bottom Sheet (137 mm ) Kg 61 435 26,522 65 40,950
Sub Total 26,522 40,950
Annual Report - 86
Aluminium Foil: Unit Quantity Rate Amount Quantity Amount
Adcet Bolus Kg 95.38 750 71,535 58.41 43,837
Adrizul Bolus Kg 50.70 860 43,602 36.73 31,680
Adsulph Bolus Kg - 860 - 57.96 49,991
Adsulph S Bolus Kg - 860 - 60.07 51,810
Adtetra Bolus Kg 26.79 860 23,039 46.79 40,356
Adzinc Bolus Kg 3.47 860 2,984 6.47 5,580
Adzyl Bolus Kg 72.41 750 54,308 20.40 14,994
Advit CP Plus Bolus Kg 67.00 860 57,620 73.00 60,444
Apetonic Bolus(137 mm) Kg 49.00 750 36,750 28.98 21,749
Adprozine Bolus Kg 51.15 760 38,874 35.00 26,600
Keto Pain Bolus Kg 49.55 760 37,658 - -
Adcipcin Bolus Kg 33.60 760 25,536 - -
TCL Bolus Kg 38.91 760 29,572 - -
Sub Total 421,478 347,041
Aluminium Disk: Unit Quantity Rate Amount Quantity Amount

Aluminium Disk-1 Ltr. Kg 36.20 1,000 36,200 13.68 13,680
Aluminium Disk -500 ml for big Cap Kg 29.00 1,000 29,000 25.71 25,710
Aluminium Disk for 500 ml narrow Cap Kg 26.26 1,000 26,260 29.00 29,003
Alu Disk-2" Kg 63.00 1,000 63,000 18.81 18,805
Alu Disk-3" Kg 46.00 1,000 46,000 17.82 17,815
Alu Disk-3.5" Kg 40.50 1,000 40,500 - -
Alu Disk-4" Kg 31.39 1,000 31,390 4.58 4,575
Sub Total 272,350 109,588
Miscellaneous: Unit Quantity Rate Amount Quantity Amount

Gum Tape # 2.5" Pcs 2,995 30.00 89,850 1,074 32,220
Scotch Tape # 1/2" Pcs 1,450 8.00 11,600 89 623
Poly Bag (Black) Kg - - - 7 1,225
Cotton Thread Pcs 1,320 70.00 92,400 14 700
Cable Tie Pcs 1,500 0.50 750 500 200
Sub Total 194,600 34,968
Grand Total 6,779,356 5,387,502
Annual Report - 87
Advent Pharma Ltd.
Trade & Other Receivables
As at June 30, 2019
Annexure-C
30-Jun-19 30-Jun-18
Abdullah Medicine House 55,663 238,547
Abid Poultry - 206,239
Abir Pharmacy - 136,243
Abdullah Pharmacy - 166,472
Abdullah Pharmacy 3,470 217,780
Abdullah Poultry Feed 77,582 133,712
AB Enterprise - 159,299
Abid Pharmacy - 176,965
Abir Pharmacy 8,352 130,793
Abodan Poultry - 98,474
AB Traders - 102,409
Abida Medical Hall 14,695 296,100
Abul Hazi Enterprise - 118,409
Adhunik Prani Chikitshaloy 245,250 183,972
Adnan Poultry & Feed 204,310 143,652
Adorsha Pharmacy 278,542 116,814
Afsana Poultry Feed 155,240 18,355
Adorsha Pharmacy 207,856 149,643
Adorsha Poshu Chikitsaloy - 210,975
Adorsha Veterinary 5,008 78,017
Afruz Veterinary - 229,069
Ahnaf Poultry Feed & Medicine 242,470 272,435
Ahmed Pharmacy - 182,129
Akash Pharmacy 224,665 198,939
Akhi Amin Pharmacy 3,642 190,626
Akhi Pharmacy 1,344 197,825
Aklima Medical Hall - 180,264
Akondo Pharmacy 156,980 86,968
Akota Agrose Trading 314,365 252,362
Akota Pharmacy 326,540 264,843
Akota Poultry Feed 178,965 131,073
Akter Poultry 315,698 259,759
Akota Poultry 32,890 84,645
Akter Veterinary - 76,483
Alal Veterinary Medicine - 82,890
Alamgir Eashat Pharmacy 301,458 157,924
Alamgir Pharmacy 2,256 216,776
Alamgir Poultry Feed 324,156 227,759
Alamin Pharmacy 278,965 243,006
Alamin Pharmacy 305,781 222,646
Annual Report - 88
30-Jun-19 30-Jun-18
Alam Medical Hall 268,793 239,175
Alamin Poultry & Fish Center 253,014 110,930
Al Fala Pharmacy 102,345 169,985
Alam Pharmacy 46,220 18,882
Al- Arafapoultry Feed & Medicine 360,245 297,913
Alif Poultry Feed 199,752 157,956
Almas Poultry Feed 304,500 265,383
Babu Enterprise 265,300 193,616
Babul Pharmacy 324,815 212,970
Babul Traders 325,480 276,899
Babu Pharmacy 388,302 206,917
Bagabari Pharmacy 105,420 170,431
Bahar Medical Hall 221,452 219,748
Bakku Poultry Feed 225,400 923,491
Bangali Veterinary 226,541 176,591
Bangladesh Pharmacy 55,230 125,071
Bangladesh Veterinary 235,610 207,771
Bijoy Poultry Farm 215,478 169,090
Bhai Bhai Poultry 101,452 126,408
Biddut Medical Hall 236,420 178,422
Bismillah Poultry & Feed Center 158,462 13,006
Biswas Medicine 78,562 98,320
Brothers Poultry 106,548 113,450
Basar Pharmacy 204,568 277,221
Beauty Pharmacy 245,687 214,481
Bhai Bhai Medical Hall 302,145 279,674
Bhai Bhai Pharmacy 245,874 143,580
Bhai Bhai Poultry 88,965 80,660
Bhai Bhai Poultry& Dairy 75,624 37,140
Bismillah Feed & Medicine 360,245 137,432
Bismillah Medical Hall 324,568 250,829
Bismillah Medicine Corner 201,458 224,378
Bismillah Medicine House 165,784 103,570
Bismillah Pharmacy 62,458 32,552
Bismillah Poultry Complex 125,478 151,409
Chandan Pharmacy 58,796 17,295
Chatmohor Poultry 350,182 210,845
Chowdhury Traders 412,540 296,485
Chowdhury Pharmacy 145,789 65,545
Dynamic Pharmacy 123,658 151,932
Dui Bhai Pharmacy 211,458 218,891
Annual Report - 89
30-Jun-19 30-Jun-18
Dairy Feed & Medicine Ghor 386,210 295,621
Datta Pharmacy 265,479 198,150
Day Night Pharmacy 203,412 208,533
Dewan Pharmacy 345,874 252,727
Diana Poultry 228,143 260,470
Dash Medicine Corner 206,547 145,671
Dewan & Braders Enterprize 96,124 58,017
Digital Poultry 96,458 46,497
Dipa Pharmacy 74,589 31,841
Doctors Veterinary 301,479 269,588
Domar Poultry Network 305,497 265,714
Dr. Joban Medical Hall 198,763 231,272
Eva Poultry Feed & Medicine 224,587 73,744
Esha Enterprize 156,324 59,344
Farhan Poultry Feed 98,746 120,040
Faruk Pharmacy 225,478 189,857
Fayza Poultry 245,871 75,834
Ferdous Medical Hall 135,487 69,370
Five Brothers Poultry 201,478 152,507
Fariya Pharmacy 235,483 129,992
Faruk Medical Store 111,736 188,280
Fatema Medicine Supply 245,871 199,752
Faruk Medicine Corner 155,687 60,954
Faumif Traders 452,136 294,968
Fokir Veterinary 485,652 313,148
Forid Pharmacy 301,472 208,337
Forkan Veterinary Store 248,756 150,999
Fozlu Pharmacy 328,711 253,055
Friends Traders 306,547 240,622
General Poultry Feed 203,499 217,580
Galib Poultry 145,879 135,546
Giyash Pharmacy 46,324 9,959
Golden Poultry 52,369 39,003
Habibul Store 301,478 265,612
Halima Pharmacy 108,796 156,754
Hamid Poshu Chikishaloy 304,789 279,301
Hanim Medicine 335,489 231,321
Hafiza Poultry & Fish Center 301,247 223,179
Hafizul Pharmacy 145,786 231,486
Helal Poultry 113,247 16,994
Hanif Pharmacy 201,689 154,574
Hazi Veterinary 312,489 121,125
Hitler Pharmacy 288,135 304,673
Hobby Pharmacy 219,475 241,888
Hoimonti Traders 245,783 262,026
Annual Report -90

30-Jun-19 30-Jun-18
Horidash Pharmcy 246,795 243,253
Insaf Veterinary 46,396 365,425
Islam Pharmacy 103,478 143,909
Islam Poultry Feed 324,785 120,756
Jahangir Medical Hall 305,478 254,110
Jalal Pharmacy 235,478 151,352
Jamal Traders 265,893 260,005
Janani Poultry 485,247 318,660
Jannatul Pharmacy 355,471 285,449
Jasim Dairy Farm 148,596 48,510
Jonokollan Poultry 321,458 239,142
Jonony Pharmacy 485,245 305,048
Jonota Medical Hall 305,478 238,334
Jonota Poshu Chikitshaloy 328,745 331,352
Joshim Pharmacy 203,145 235,639
Joshim Poultry Feed 347,896 245,796
Joti Pharmacy 374,598 254,985
Jui Pharmacy 248,695 183,026
Karim Pharmacy 278,965 231,273
Kawsar Pharmacy 301,478 221,723
Kazol Enterprize 269,874 108,508
Kazol Veterinary 395,874 163,648
Kofil Uddin Homio & Veterinary Medical Store 185,695 88,688
Konok Veterinary 201,458 164,099
Krishno Traders 203,145 212,184
Kawsar Dairy Farm 152,632 76,440
Kamal Pharmacy 33,843 89,102
Khan Poultry Medicine 45,789 1,006
Khoka Traders 152,369 4,984
Kalam Poultry Feed 147,856 201,677
Khondakar Medical Hall 351,200 198,032
Lamiya Poultry 121,458 15,477
Liza Enterprize 103,589 38,936
Lemon Pharmacy 358,410 275,933
Liton Medical Store 410,253 205,336
Liza Pharmacy 345,789 242,434
Lotif Pharmacy 201,458 235,366
Maa Baba Poultry 203,145 212,671
Maa Babar Doa Poultry 412,563 252,864
Maa Chikitshaloy 245,874 112,322
Maa Fatema Pharmacy 245,789 167,476
Maa Medical Hall 201,457 135,324
Maa Medical Store 475,698 372,332
Maa Medicine Corner 452,368 325,455
Maa Pharmacy 352,147 273,866
Annual Report - 91
30-Jun-19 30-Jun-18
Maa Traders 356,840 219,231
Maa Veterinary Oushodh Gorh 201,457 157,314
Mahafuz Pharmacy 378,954 291,016
Mahatab Pharmacy 245,874 190,753
Mahfuz Pharmacy 345,697 273,680
Mahfuz Veterinary 354,126 272,963
Makka Poultry 379,659 273,556
Manaf Medical Hall 206,478 209,666
Master Pharmacy 365,781 294,453
Master Feed Agrotec Ltd. 301,695 -
Masud Medical Hall 412,578 280,517
Masud Pharmacy 412,563 214,577
Masum Traders 345,879 280,562
Matiur Pharmacy 385,410 272,775
Mazeda Pharmacy 365,214 267,279
Mehedi Hasan Pharmacy 247,896 248,160
Merina Pharmacy 347,596 258,828
Milon Enterprise 243,659 142,487
Mim Pharmacy 72,896 247,682
Modern Pharmacy 88,654 139,698
Modern Veterinary 92,354 209,057
Modhu Pharmacy 197,143 284,360
Modina Veterinary 432,125 204,668
Mollah Pharmacy 126,336 170,463
Monira Pharmacy 301,654 229,525
Monosha Pharmacy 462,314 248,175
M.S Talukdar Poultry 363,254 185,251
M.S Tamanna Poultry 290,124 167,253
Muklas Veterinary 456,812 333,394
Mukta Veterinary 271,784 236,231
Munshi Medical 249,872 197,605
Mustakin Traders 54,186 138,621
Musa Enterprize 266,354 64,505
M.S Progoti Poultry,Medicine & Feed 31,245 51,356
M/S Kobir Poultry Feed 63,241 6,341
Naba Pharmacy 358,796 281,356
Nahar Pharmacy 401,247 277,880
Nasim Veterinary Store 247,563 156,031
Nayem Pharmacy 352,123 276,983
Nayem Veterinary 40,986 179,060
Nazmoon Pharmacy 339,854 287,066
Nazmul Traders 235,684 185,806
Niven Veterinary 309,652 203,545
Nokshi Pharmacy 324,570 180,992
Nurul Veterinary 365,890 231,454
Annual Report - 92
30-Jun-19 30-Jun-18
Nur Poultry 81,245 7,160
New Abir Trders 132,540 32,224
Niloy Vet Pharmacy 336,540 264,496
Nasir Pharmacy 99,214 40,150
Naf Veterinary Hospital 10,314 86,630
Opu Pharmacy 204,587 190,942
Oushodh Bitan 232,158 205,182
Oushodh Gorh 409,547 207,679
Omi Poultry Feed & Medicine Center 123,458 52,650
Pirgacha Agro Service 103,982 145,380
Poltu Pharmacy 111,426 120,493
Popular Pharmacy 133,254 199,788
Poshu Pakhi Medicine 263,159 212,407
Poshu Shastho Pharmacy 76,646 217,642
Poshu Sheba Pharmacy 263,124 156,342
Prani Oushadaloy 345,875 133,585
Protima Pharmacy 221,356 180,113
Padma Poshu Chikitshaloy 87,541 14,940
Palong Poultry Feed & Medicine Center 365,890 203,920
Polash Shemul Pharmacy 120,345 54,388
Rafiq Pharmacy 288,542 104,784
Rahad Poultry 302,154 102,626
Rahman Pharmacy 254,630 131,500
Raihan Pharmacy 302,145 253,587
Rakib Traders 224,578 187,726
Rangdhonu Medicine Corner 365,324 205,038
Rangpur Poultry& Dairy 265,315 142,474
Razzak Veterinary 332,546 107,074
Raihan Medical Hall 313,548 274,647
Rita Pharmacy 263,548 159,036
Rog Mukti Pharmacy 307,546 261,253
Roman Poultry 135,684 53,500
Ripon Medical Hall 201,458 114,158
Rimi Poultry 235,489 95,048
Ready Stock 156,841 99,534
Sad Enterprize 254,682 184,015
Sadiqul Poultry 330,152 180,068
Sagor Poultry Feed 302,148 192,087
Saju Pharmacy 156,841 265,810
Samia Pharmacy 132,564 142,689
Samsunahar Pharmacy 201,658 216,716
Sarder Poultry & Feed 122,457 16,447
Sarker Drug House 165,241 81,946
Sarker Pharmacy 288,599 168,069
Sathi Pharmacy 237,458 166,954
Annual Report - 93
30-Jun-19 30-Jun-18
Seyam Pharmacy 301,245 143,766
Shahalom Veterinary 332,458 235,045
Shahin Traders 286,524 145,351
Shiblu Medical Hall 301,245 167,500
Shown Pharmacy 203,458 149,059
Sunil Pharmacy 145,682 23,519
Suvro Medical Hall 204,578 82,715
Sumon Pharmacy 220,145 105,632
Sumiya Poultry feed & Medicine 183,214 49,261
Taiabiya Medical Hall 245,876 110,418
Tamim Poultry Feed & Medicine 133,423 49,280
Tanjit Pharmacy 145,872 67,798
Tarek Poultry Feed & Medicine 231,458 125,280
Tasnin Poultry 32,548 51,344
Taz Poultry 242,578 131,427
Tisha Pharmacy 63,254 12,172
Tofazzol Pharmacy 77,893 11,311
Towhid Poultry Feed 31,547 44,471
Tutul Traders 142,156 30,254
Uddyog Poultry 108,974 41,786
Ullahpara Medical Hall 349,333 64,969
Upom Poultry 141,968 60,363
Uttara Pharmacy 142,356 82,152
Uzzal Poultry 47,589 9,528
Vasha Pharmacy 101,458 26,695
Veterinary Store 214,587 119,604
Yeakub Pharmacy 87,456 99,546
Younus Enterprize 103,548 52,823
Zarin Poultry 245,876 170,294
Zihadh Veterinary 131,242 69,662
Zohir Traders 268,791 154,516
Zohir Enterprise 214,587 158,016
Wazid Veterinary 136,597 13,118
Vula Pharmacy 66,879 6,110
Veterinari Clinic 54,682 5,672
Veterinary Oushudh Ghor 113,458 13,312
Vet Fish & Medicine Corner 165,789 13,014
A.D Medicine Corner 166,453 25,874
Adnan Enterprise 102,458 42,690
Akhi Boiler House 206,548 85,275
A.K Medical Store 177,963 25,680
Babu Khamari 134,580 31,254
Bangla Bazar Poultry 102,345 37,452
Bappi- Kiron Poultry Feed 356,306 98,650
Annual Report - 94
30-Jun-19 30-Jun-18
Bashar Pharmacy 135,690 21,658
Bina Pharmacy 214,587 31,568
Chanmia Pharmacy 166,354 25,450
City Pharmcy 210,354 23,580
Dairy Poultry Medicine Corner 213,420 48,256
Darussalam Medical Hall 54,365 75,620
Eman Pharmacy 173,185 12,450
Farzana Pharmacy 131,247 11,250
Omar Pharmacy 244,150 33,650
Gobadi Poshu Corner 236,129 50,260
Gourohori Medical Hall 245,783 42,560
Harun Pharmacy 312,584 124,150
Hashu Poultry Feed 278,450 25,480
H & M Enterprise 99,756 28,650
Ikra Medical Hall 106,451 42,580
Islam Traders 227,407 75,845
Jarnalit Pharmacy 201,345 61,240
Ashim Veterinary 129,419 -
Ashik Poultry 253,125 -
Bismillah Medicine House 215,125 -
Bhai Bon Pharmacy 360,081 -
M.S Hamida Pharmacy 243,317 -
Mollika Poultry Feed 276,178 -
Payker Pharmacy 51,008 -
Poshu Oshud Jogoth 146,123 -
Rasel Veterinary Store 89,752 -
Rafiza Pharmacy 38,058 -
Rupa Medical Store 42,983 -
Sathi Poultry & Dairy 323,313 -
Sayma Pharmacy 251,407 -
S Enterprise 31,657 -
Shescha Sheba Krittim Projonon Kendro 253,839 -
Tarek Pharmacy 31,904 -
Hazi Pharmacy 294,182 -
Jobbar Pharmacy 250,312 -
Krishno Veterinary 22,072 -
Emon Pharmacy 265,994 -
Islam Traders 60,329 -
Seyam Enterprise 132,844 -
Four Star Poultry Feed Centre 184,271 -
Alvida Poultry & Feed 55,507 -
Ahmed Veterinary 486,408 -
Afrin Dairy & Poultry 57,816 -
Chatmohor Poultry 350,183 -
Annual Report - 95
30-Jun-19 30-Jun-18
Emon Pharmacy 265,995 -
Faumif Traders 21,901 -
Feroz Poultry 74,778 -
Forida Pharmacy 102,851 -
Fozlu Pharmacy 66,789 -
Galib Poultry 66,628 -
Hasan Poultry Feed 13,452 -
Jobbar Pharmacy 250,312 -
Jononi Traders 223,713 -
Joya Poultry Feed & Medicine 59,710 -
Kalam Poultry Feed 223,578 -
Keya Bagan Pharmacy 112,117 -
Khan Pharmacy 57,351 -
Mannan Poultry 514,377 -
Maltasha Poultry 29,216 -
Master Poultry-2 112,977 -
Miya Pharmacy 35,875 -
Modhu Pharmacy 197,143 -
M.S Aditto Agro 30,064 -
M.S Bipu Bech Bondor 43,164 -
M.S Borol Poultry 19,564 -
M.S Hamida Pharmacy 243,317 -
Ms Jaman Pharmacy 39,197 -
M.S Muradh Traders 146,335 -
Nahian Poultry Feed 30,625 -
Nondita R-71 Poultry Feed (Rangpur) 20,591 -
Pakhi Ghor 74,989 -
Payker Pharmacy 51,008 -
Poshu Oshud Jogoth 146,123 -
Rahul Pharmacy 56,040 -
R.K Medicine Center 30,617 -
Robi Poultry 206,601 -
Rupa Medical Store 42,983 -
Saiful Poultry 20,171 -
Sathi Poultry & Dairy 323,314 -
Sayma Pharmacy 251,407 -
Shahitto Poultry Media 44,378 -
Shahjalal Medicine 51,252 -
Shescha Sheba Krittim Projonon Kendro 253,839 -
S K Medicine 41,664 -
Sownik Poultry Feed & Medicine 64,256 -
Tarek Pharmacy 31,904 -
Tuhin Enterprize 235,594 -
Udoyon Poultry Feed 37,752 -
Yousuf Poultry 20,123 -
Annual Report - 96
30-Jun-19 30-Jun-18
Zia Poultry & Medicine 20,835 -
Taysha Poultry Feed & Medicine Corner 35,430 -
Total 78,850,747 52,017,501
Annual Report - 97
Advent Pharma Ltd.
Schedule of Sales
For the year 2018-2019
Finished Goods Annexure-D
Product Rate / 30-Jun-19 30-Jun-18

Name of Product Unit
Category Unit Quantity Amount Quantity Amount
ADLYTE Powder 100 gm Powder Sachet 20.00 282,699 5,653,980 197,704 3,954,080
ADLYTE Powder 500 gm Powder Sachet 80.00 192,708 15,416,640 107,708 8,616,640
ADLYTE Powder 1 kg Powder Sachet 120.00 198,705 23,844,600 123,705 14,844,600
ADVIT GC Powder 500 gm Powder Sachet 85.00 181,444 15,422,740 135,844 11,546,740
ADVIT GC Powder 1 kg Powder Sachet 160.00 153,023 24,483,680 108,023 17,283,680
ADVIT C Powder 100 gm Powder Sachet 165.00 144,598 23,858,670 109,598 18,083,670
ADVIT C Powder 500 gm Powder Sachet 390.00 490 191,100 - -
ADVIT DB Powder 100 gm Powder Sachet 28.00 386,002 10,808,057 341,802 9,570,456
ADVIT DB Powder 500 gm Powder Container 125.00 217,176 27,147,000 154,176 19,272,000
ADVIT DB Powder 1 kg Powder Bucket 235.00 162,291 38,138,385 117,291 27,563,385
Advomica Powder 10x20gm Powder Box 92.26 11,826 1,091,070 35,625 3,286,763
Ad-Tetra 100 gm Powder Sachet 64.46 4,251 274,019 52,751 3,400,329
Adprolim Plus 100 gm Powder Sachet 203.76 1,192 242,882 38,192 7,782,002
Adlinsin 100 gm Powder Sachet 252.43 2,203 556,103 37,957 9,581,486
Adlinsin 500 gm Powder Container 1,124.78 617 693,989
Adlosin Powder-100 gm Powder Container 605.00 1,413 854,865
Adbovi Powder 125 gm Powder Sachet 180.00 44,749 8,054,820 32,449 5,840,820
Adcal P 500 gm Powder Sachet 250.00 49,674 12,418,500 34,254 8,563,500
Adcal P 250 gm Powder Sachet 130.00 1,343 174,590
Adzyme Powder 100 gm Powder Sachet 140.00 52,910 7,407,400 43,710 6,119,400
Colis Vet 100 gm Powder Sachet 128.05 1,881 240,862 18,400 2,356,120
Colis Vet 500 gm Powder Container 569.60 1,333 759,277 5,189 2,955,654
Neocin Vet 100 gm Powder Sachet 220.44 1,025 225,951 7,391 1,629,272
Neocin Plus Vet 100 gm Powder Sachet 285.44 2,227 635,675 8,342 2,381,140
Egg Bost-100 gm Powder Sachet 130.00 17,796 2,313,480 - -
Egg Bost-500 gm Powder Container 625.00 5,520 3,450,000 - -
Power Fat-1 kg Powder Sachet 275.00 16,001 4,400,275 - -
Advit(B+C)-100 gm Powder Sachet 48.00 35,097 1,684,656 - -
Advit(B+C)-500 gm Powder Sachet 200.00 14,255 2,851,000 - -
Advit WS-100 gm Powder Sachet 230.00 7,093 1,631,390 - -
Advit-3 Powder-100 gm Powder Sachet 75.00 992 74,400
Microfix 100 gm Powder Sachet 275.22 2,533 697,132 5,762 1,585,818
Advit CP Suspension 500 ml Liquid Bottle 110.00 249,681 27,464,910 183,861 20,224,710
Advit CP Suspension 1 ltr Liquid Bottle 190.00 179,382 34,082,580 133,510 25,366,900
Advit CP Suspension 5 ltr Liquid Jar 800.00 52,696 42,156,800 36,346 29,076,800
ADZINC SYRUP 100 ml Liquid Bottle 30.00 251,808 7,554,240 155,989 4,679,670
ADZINC SYRUP 500 ml Liquid Bottle 110.00 194,254 21,367,940 169,674 18,664,140
ADZINC SYRUP 1 Litre Liquid Bottle 200.00 176,169 35,233,800 140,759 28,151,800
ADZINC SYRUP 3 Litre Liquid Container 560.00 6,655 3,726,800 - -
ADVIT - D PLUS SOLUTION
Liquid Bottle 70.00 144,749 10,132,430 99,749 6,982,430
100 ml
Annual Report - 98
Product Rate / 30-Jun-19 30-Jun-18
Name of Product Unit
Category Unit Quantity Amount Quantity Amount
Adcipcin 100 ml Liquid Phyle 175.94 2,383 419,265 10,183 1,791,597
Adcipcin 500 ml Liquid Bottle 814.79 952 775,680 - -
Advit AD3E Solution 100 ml Liquid Bottle 130.00 43,849 5,700,370 29,329 3,812,770
Advit AD3E Solution 500 ml Liquid Bottle 590.00 28,632 16,892,880 16,182 9,547,380
Adzuril Solution 100 ml Liquid Bottle 370.00 1,929 713,730 8,146 3,014,020
Advit E-Sel 100 ml Liquid Phyle 85.00 68,633 5,833,805 14,063 1,195,355
Cough Off 100 ml Liquid Phyle 95.00 42,102 3,999,690 19,572 1,859,340
Cough Off 500 ml Liquid Jar 460.00 12,351 5,681,460 7,351 3,381,460
Cough Off 1 ltr. Liquid Jar 880.00 9,027 7,943,760 4,774 4,201,120
ABC Solution 100 ml Liquid Phyle 90.00 69,043 6,213,870 12,362 1,112,580
ABC Solution 500 ml Liquid Jar 370.00 27,261 10,086,570 5,911 2,187,070
ABC Solution 1 ltr. Liquid Jar 695.00 29,407 20,437,865 4,897 3,403,415
Feron Vet 500 ml Liquid Jar 100.00 61,002 6,100,200 18,502 1,850,200
Feron Vet 1 Ltr. Liquid Jar 190.00 49,742 9,450,980 6,232 1,184,080
Liver On 100 ml Liquid Phyle 70.00 110,390 7,727,300 15,391 1,077,370
Liver On 500 ml Liquid Jar 310.00 34,085 10,566,350 7,785 2,413,350
Liver On 1 ltr. Liquid Jar 585.00 30,759 17,994,015 6,259 3,661,515
Nephrosol 100 ml Liquid Phyle 190.00 22,147 4,207,930 13,640 2,591,600
Nephrosol 500 ml Liquid Phyle 900.00 6,218 5,596,200 - -
Oramin Solution-100 ml Liquid Bottle 110.00 33,453 3,679,830 - -
Oramin Solution-500 ml Liquid Bottle 510.00 11,377 5,802,270 - -
Advit B Complex-100 ml Liquid Bottle 85.00 47,556 4,042,260 - -
Advit B Complex-500 ml Liquid Bottle 390.00 28,055 10,941,450 - -
Advit CP Plus Bolus (10*2) Bolus Box 70.00 - - 1,032 72,240
Adrizole Bolus Bolus Box 122.43 2,864 350,640 19,570 2,395,955
Adcet Bolus Bolus Box 33.40 7,132 238,209 58,523 1,954,668
Ad-Tetra Bolus Bolus Box 45.91 1,131 51,924 35,833 1,645,093
Adsulph Bolus Bolus Box 243.50 1,319 321,177 6,335 1,542,573
Adsulph-S Bolus Bolus Box 243.50 1,107 269,555 6,238 1,518,953
Apetonic Bolus Bolus Box 102.78 2,581 265,275 18,013 1,851,376
Advit CP Plus Bolus (20*2) Bolus Box 135.00 77,484 10,460,340 124,306 16,781,310
Adzyle Bolus Bolus Box 72.61 2,322 168,600 8,785 637,879
Adprozine Bolus(10x4) Bolus Box 99.57 2,157 214,772 - -
Keto Pain Bolus(5x4) Bolus Box 150.22 1,850 277,907 - -
Keto Pain Bolus(10x4) Bolus Box 300.44 760 228,334 - -
TCL Vet Bolus(5x4) Bolus Box 302.17 1,746 527,589 - -
Adcipcin Bolus(10x2) Bolus Box 300.70 709 213,196 - -
Oxi D Bolus Bolus Container 240.00 644 154,560 - -
Total 601,966,497 396,048,274
Annual Report - 99

Advent Annuual Report-2018-19 PDF

Uploaded by

Document Information

Original Title

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Advent Annuual Report-2018-19 PDF

Uploaded by

Copyright:

Available Formats

TABLE OF CONTENTS

Notice of the 12th Annual General Meeting (AGM)

02. To declare dividend as recommended by the Board of Directors.

03. To elect/re-elect Directors as per Articles of Association of the Company.

By order of the Board

Name of the Company : Advent Pharma Limited

Legal Status : A Public Company limited by shares registered under companies

Date of Incorporation : C-65459(2951)/2007 dated: 25.01.2007

Converted into Public Limited Company : 07-May-2016

Commencement of Commercial Operation : 01-March -2013

Production Capacity : Bolus Products (in Pcs): 15.12 Million Pcs/Year

Nature of Business :The Company is a Pharmaceutical company which is engaged in

Authorized Capital : BDT 1,000 million

Paid Up Capital : BDT 754.60 million

Date of Approval for IPO : January 11, 2018

Date of Listing with DSE : April 01, 2018

Date of Listing with CSE : March 28, 2018

External Auditors : Ahmed Zaker & Co., Chartered Accountants

Credit Rating Agency : Alpha Credit Rating Ltd.

Company’s Website : www.adventpharmabd.com

Brief description of business strategy;

1. To be dedicated for the production of animal health care drugs;

Mr. A.K.M Shafiqul Alam, LLB Chairman

Mr. Wajhi Ahmed Managing Director

Mrs. Kazi Rina Alam Director

Mrs. Faria Binta Alam Director

Mr. Md. Tazul Islam Director

Mr. Mohammad Towhidul Islam Director

Mr. Asif Iqbal Chowdhury Director

Mr. Mohammed Salim, MBA, FCMA Independent Director

Mr. Sheikh Karimuzzaman Independent Director

Mr. Sheikh Karimuzzaman Member

Mr. Asif Iqbal Chowdhury Member

Mr. Ikramul Islam Member Secretary

Nomination and Remuneration Committee (NRC)

Mr. Mohammed Salim, MBA, FCMA Chairman

Mr. A.K.M Shafiqul Alam Member

Mr. Mohammad Towhidul Islam Member

Mr. Ikramul Islam Member Secretary

Mr. A.K.M Shafiqul Alam, LLB

Kazi Rina Alam,

Faria Binta Alam,

Md. Tazul Islam,

Mohammad Towhidul Islam,

Asif Iqbal Chowdhury,

Bismillahir Rahmanir Rahim

Respected Members, Shareholders and other Stakeholders,

Bismillahir Rahmanir Rahim

Bismillahir Rahmanir Rahim

Year National Market Growth Rate Company’s Growth Rate

2014-15 11.36% 35.00%

Source: IMS Report, 2018

Particular 2018-19 2017-18

Industry outlook and possible future developments in the industry

SEIVING & SIFTING

ADDITION & MIXING

FILLING INTO BOTTLES/CONTAINERS

LABELLING & PACKING

TRANSFER TO FG STORE FOR SALES AND DISTRIBUTION

B. Process Flow Sheet for Manufacture of Powder Preparation

SEIVING & SIFTING

DRYING BY FLUID BED DRYING

BLENDING IN CONE SHAPE BLENDER